Ohne Titel - Univ.-Prof. Dr. Michael Gnant

Univ. Prof. Dr. Michael Gnant
1
Originalarbeiten
-1-
Muehlbacher F, Steininger R, Laengle F, Sautner T, Gnant M, Goetzinger P, Piza F, Popow T
OKT 3 immunoprophylaxis in human liver transplantation
Transplant P 1989; 21: 2253-4
2
IF: 1,096
Sautner T, Graninger G, Gnant M, Jantsch H
Adjuvante Therapie einer Pseudomonaspneumonie und -sepsis bei einer immunsupprimierten
Patientin nach orthotoper Lebertransplantation mit einer IgM-angereicherten Immunglobulinloesung
und Fibronectin-angereichertem
Acta
Chir Austriaca 1989; 6: 304-5 Serum
IF: 0,000
3
Muehlbacher F, Steininger R, Laengle F, Hamilton G, Sautner T, Gnant M, Goetzinger P, Piza F, Popow T
Prophylaxis with OKT 3 for liver transplantation
Transplant P 1989; 21 Suppl 2: 25-30
4
IF: 1,096
Gnant M, Sautner T, Muehlbacher F, Steininger R, Laengle F, Piza F
Professionelle Organgewinnung als Vorraussetzung zum Erreichen der notwendigen
Transplantationsfrequenz: Erfahrungen mit der Organspende am Transplantationszentrum Wien
Wiener Klin Wochenschr 1989; 23: 824-8
5
IF: 0,245
Laengle F, Gnant M, Sautner T, Muehlbacher F, Kretschmer G, Traindl O, Kovarik J, Derfler K, Balcke B, Steger H, Hajek
A, Piza F
Erfahrungen und klinische Ergebnisse nach 99 Verwandtennierentransplantationen
Wiener Klin Wochenschr 1989; 5: 148-51
6
IF: 0,216
Muehlbacher F, Gnant M, Auinger M, Steininger R, Klauser R, Prager R, Karnel F
Pancreatic venous drainage to the portal vein: A new method in human pancreatic transplantation
Transplant P 1990; 22: 636-7
7
IF: 0,987
Steininger R, Fuegger R, Hackl W, Hamilton G, Herbst F, Laengle F, Gnant M, Rogy M, Sautner T, Schulz F, Muehlbacher
F
Immediate graft function after OLT clears endotoxins
Transplant P 1990; 22: 1544-6
8
IF: 0,987
Funovics J, Gnant M, Piza F
Zur Neubewertung der Indikation zur Lebertransplantation
Leber-Magen-Darm 1990; 1: 7-11
9
IF: 0,227
Laengle F, Gnant M, Sautner T, Muehlbacher F, Watzinger U, Derfler K, Manker M, Piza F
Homologe Saphenavenen als AV-Shunt zur Hämodialyse: Ein Vergleich zu konventionellen
Methoden
Angio Arch 1990; 19: 171-3
IF: 0,000
2
Univ. Prof. Dr. Michael Gnant
10
Originalarbeiten
-2-
Gnant M
Aspects and prospects of organ procurement: The Vienna experience
ETCO Newsl 1990; 1: 7-10
11
IF: 0,000
Gnant M, Schoental E, Banhegyi C, Steininger R, Sautner T, Goetzinger P, Wamser P, Zekert F, Muehlbacher F
The impact of serum lipid parameters on the diagnosis of acute and chronic rejection after orthotopic
liver transplantation
Transplant Proc 1991; 23: 1434-5
12
IF: 1,064
Muehlbacher F, Huk I, Steininger R, Gnant M, Goetzinger P, Wamser P, Banhegyi C, Piza F
Is orthotopic liver transplantation a feasable treatment for secondary cancer of the liver?
Transplant P 1991; 23: 1567-8
13
IF: 1,064
Stockenhuber F, Gnant M, Apperl A, Steininger R, Sautner T, Balcke P, Muehlbacher F
Soluble interleukin-2 receptor in liver transplant recipients
Transplant P 1991; 23:1417-8
14
IF: 1,064
Roka R, Niederle B, Gnant M, Laengle F, Hausmaninger C, Neuhold N
Derzeitiger Therapieplan beim differenzierten Schilddrüsenkarzinom
Chirurg 1991; 62: 518-23
15
IF: 0,392
Sautner T, Goetzinger P, Wamser P, Gnant M, Steininger R, Muehlbacher F
Impact of donor age on graft function in 1180 consecutive kidney recipients
Transplant P 1991; 23: 2598-601
16
IF: 1,064
Gnant M, Wamser P, Goetzinger P, Sautner T, Steininger R, Muehlbacher F
The impact of presumed consent law and decentralized organ procurement system on organ
donation: quadruplication of number of organ donors
Transplant P 1991; 23: 2685-6
17
IF: 1,064
Gnant M, Rosenmayr A, Wamser P, Goetzinger P, Sautner T, Steininger R, Banhegyi C, Muehlbacher F
Prenephrectomy tissue typing using donor lymph node cells: A reliable and safe way of shortening
cadaver kidney ischemia time
Transplant P 1991; 23: 2683-4
18
IF: 1,064
Gnant M, Blijham G, Schemper M, Reiner A, Reiner G, Spona J, Reynders M, Schutte B, van Asche C, Steger G, Jakesz R
Der prognostische Stellenwert der Flowzytometrie beim Mammakarzinom: 10-Jahres-Ergebnisse
einer randomisierten Studie
Acta chir Austriaca 1991; 2: 43-8
IF: 0,000
2
Univ. Prof. Dr. Michael Gnant
19
Originalarbeiten
-3-
Steininger R, Muehlbacher F, Längle F, Gnant M, Sautner T, Goetzinger P, Walgram M, Penner E, Radaszkiewicz T
Erfahrungen mit der Lebertransplantation beim Hepatitis-B-Antigen positiver Leberzirrhose
Wien Klin Wochschr 1991; 19: 573-6
20
IF: 0,243
Banhegyi C, Sautner T, Gnant M, Goetzinger P, Wamser P, Muehlbacher F
Transplantation of shipped full-house kidneys versus local poorly matched grafts - does a shorter
cold ischemic time outweigh a worse match?
Transplant P 1991; 23: 2610-1
21
IF: 1,064
Steininger R, Muehlbacher F, Hamilton G, Laengle F, Gnant M, Popow T, Sautner T, Goetzinger P, Wamser P,
Stockenhuber F, Mirza D, Piza F
Comparison of CyA, OKT3, and ATG immunoprophylaxis in human liver transplantation
Transplant P 1991; 23: 2269-71
22
IF: 1,064
Jakesz R, Hausmaninger H, Depisch D, Kubista E, Samonigg H, Steindorfer P, Schemper M, Gnant M, Kolb R, Krauß K,
Manfreda D, Stierer M, Michlmayr G, Fridrik M, Dadak C, Hofbauer F, Horvath W, Zielinski C, Wette V, Oppitz P, Duenser
M,
Lenzhofer R, Mueller
Ludwig H;
Adler A, Aiginger
P, Bauer
D, Bauerndorfer T,bei
Beinhauer
A, Boeckl
O, Brunhofer A,
Abgeschlossene
undL,derzeit
laufende
adjuvante
Therapieprotokolle
Patienten
mit operablem
Mammakarzinom
Acta chir Austriaca 1991; 2: 63-9
23
IF: 0,000
Hamilton G, Prettenhofer M, Zommer A, Hofbauer S, Goetzinger P, Gnant M, Függer R
Intraoperative course and prognostic significance of Endotoxin, Tumor necrosis factor-alpha and
Interleukin-6 in liver transplant recipients
Immunobiology 1991; 182: 425-39
24
IF: 1,576
Sautner T, Gnant M, Goetzinger P, Wamser P, Steininger R, Muehlbacher F
Cadaveric kidney donation beyond the age of 60 - a comparative analysis of 1180 grafts from
different donor age groups
Tranplant Int 1992; 5 Suppl 1: S47-S50
25
IF: 0,907
Sautner T, Gnant M, Banhegyi C, Wamser P, Goetzinger P, Steininger R, Muehlbacher F
Risk factors for development of panel reactive antibodies and their impact on transplantation outcome
in 909 kidney grafts
Transplant Int 1992; 5 Suppl 1; S116-S120
26
IF: 0,907
Gnant M, Blijham G, Reiner A, Reiner G, Reynders M, Schutte B, van Asche C, Steger G, Jakesz R
DNA ploidy and other results of DNA Flow cytometry as prognostic factors in operable breast cancer:
10 year results of a randomized study
Eur J Cancer 1992; 28: 711-6
27
IF: 2,191
Gnant M, Sautner T, Wamser P, Goetzinger P, Rosenmayr A, Muehlbacher F
A reliable way of shortening cadaver kidney ischemia time: Prenephrectomy tissue typing using
donor lymph node cells
Tranplant Int 1992; 5 Suppl 1: S722-S724
IF: 0,907
2
Univ. Prof. Dr. Michael Gnant
28
Originalarbeiten
-4-
Gnant M, Sautner T, Rosenmayr A, Muehlbacher F
Repeated HLA mis-match in multiple kidney transplantation - Preliminary results of 146
retransplantations in the cyclosporine era
Transplant P 1992; 24: 2466-2468
29
IF: 1,125
Gnant M, Seifert M, Jakesz R, Adler A, Mittlboeck M, Sevelda P
Breast cancer and timing of surgery during menstrual cycle: A 5-year analysis of 385 premenopausal
women
Int J Cancer 1992; 52: 707-712
30
IF: 2,917
Fuegger R, Klimann S, Gnant M, Herbst F, Schulz F, Fritsch A
Laparoskopische Cholecystektomie - Auswertung einer prospektiven Beobachtungsstudie
Wien Klin Wochenschr 1992; 104/20: 640-3
31
IF: 0,196
Neuhold N, Laengle F, Gnant M, Hollenstein U, Niederle B
Relationship of CD15 immunoreactivity and prognosis in sporadic medullary thyroid carcinoma
J Cancer Res Clin 1992; 118: 629-634
32
IF: 1,820
Fuegger R, Klimann S, Gnant M, Schulz F, Fritsch A
Gallengangsverletzungen bei laparoskopischer Cholecystektomie
Helv Chir Acta 1992; 59: 571-571
33
IF: 0,046
Sautner T, Gnant M, Banhegyi C, Wamser P, Goetzinger P, Steininger R, Hajek-Rosenmayr A, Muehlbacher F
Risikofaktoren für die Entstehung lymphozytotoxischer Antikörper und deren Einfluß auf die
Organfunktion nach Nierentransplantation
Acta chir Austriaca 1992; 24: 354-8
34
IF: 0,000
Fuegger R, Herbst F, Gnant M, Goetzinger P, Sautner T, Windberger U, Siegl H, Losert U, Fritsch A
Die experimentelle laparoskopische Sigmaresektion
Min Inv Chir 1992; 1: 167-8
35
IF: 0,576
Gnant M, Sautner T, Rosenmayr A, Muehlbacher F
Tolerance induction in human kidney retransplantation: Impact of repeated HLA mismatches in 156
second renal grafts
Transplant P 1993; 25: 319-321
36
IF: 1,125
Stockenhuber F, Kramer G, Pec M, Scentkiraly A, Gnant M, Steininger R, Balcke P, Muehlbacher F
Circulating ICAM-1: Novel parameter of renal graft rejection
Transplant P 1993; 25: 919-920
IF: 1,125
2
Univ. Prof. Dr. Michael Gnant
37
Originalarbeiten
-5-
Gruenberger T, Gnant M, Sautner T, Hoebarth K, Steininger R, Hofbauer J, Muehlbacher F
Impact of vesicoureteral reflux on graft survival in renal transplantation
Transplant P 1993; 25: 1058-1059
38
IF: 1,125
Steger G, Mader R, Gnant M, Marosi C, Lenz K, Jakesz R
GM-CSF in the treatment of a patient with severe methotrexate intoxication
J Intern Med 1993; 233: 499-502
39
IF: 1,453
Gnant M, Blijham G, Schemper M, Reiner A, Reiner G, Spona J, Reynders M, Schutte B, van Asche C, Steger G, Jakesz R
Aneuploidy Fraction but not DNA Index is important for the prognosis of patients with stage I and II
breast cancer - 10 year results
Ann Oncol 1993; 4: 643-650
40
IF: 2,064
Hamilton G, Vogel S, Fuegger R, Gnant M
Mechanisms of tumor necrosis factor-a and interleukin-6 induction during human liver transplantation
Mediat Inflamm 1993; 2: 303-307
41
IF: 0,870
Wamser P, Goetzinger P, Gnant M, Sautner T, Steininger R, Muehlbacher F
What do intensive care unit personell think about organ donation? Opinion poll amongst transplant
centers
Transplant P 1993; 25:3122-3
42
IF: 1,125
Fuegger R, Herbst F, Gnant M, Sautner T, Goetzinger P, Windberger U, Siegl H, Losert U, Fritsch A
Laparoskopische Kolonchirurgie - vom Experiment zu ersten klinischen Erfahrungen
Wien Klin Wochenschr 1993; 105: 544-548
43
IF: 0,268
Wamser P, Goetzinger P, Steininger R, Gnant M, Sautner T, Muehlbacher F
Discontinuing of a permanent information and education program among donors ICUs leads to a 50%
decrease of organ donor rates
Transplant P 1993; 25: 2988-9
44
IF: 1,125
Gnant M, Wamser P, Barlan M, Muehlbacher F
Impact of donor cause of death on renal graft function - a multivariate analysis of 1545 kidney
transplants
Transplant P 1993; 25: 3102-3
45
IF: 1,125
Goetzinger P, Gnant M, Hochstoeger E, Jakesz R
The potential impact of Tamoxifen in Breast Cancer Prevention
Onkologie 1993; 16: 297-303
IF: 0,545
2
Univ. Prof. Dr. Michael Gnant
46
Originalarbeiten
-6-
Steger GG, Mader RM, Djavanmard MP, Gnant M, Locker G, Marosi C, Rainer H, Jakesz R
Double modulation of 5-flourouracil by high-dose leucovorin and interferon a2b in advanced
colorectal cancer: A phase I and a phase II study of weekly administration
J Cancer Res Clin Oncol 1994; 120: 314-318
47
IF: 1,820
Mader RM, Steger GG, Rizovski B, Sieder AE, Locker G, Gnant M, Jakesz R, Rainer H
Pharmacokinetics of rac-leucovorin versus [S]-leucovorin in patients with advanced gastrointestinal
cancer
Brit J Clin Pharmac 1994; 37: 243-248
48
IF: 1,922
Wamser P, Goetzinger P, Barlan M, Gnant M, Hoelzenbein T, Watschinger B, Muehlbacher F
Reasons for 50% reduction in the number of organ donors within 2 years - opinion poll amongst all
ICUs of a tranplant centre
Transplant Int 1994; 7 [Suppl 1]: S668-671
48A
IF: 0,907
Wamser P, Goetzinger P, Barlan M, Gnant M, Hoelzenbein T, Watschinger B, Muehlbacher F
Reasons for 50% reduction in the number of organ donors within 2 years - opinion poll amongst all
ICUs of a tranplant centre
Eurotransplant Newsletter 1994; 116: 6-9
49
IF: 0,000
Rudas M, Gnant M, Mittlboeck M, Neumayer R, Kummer A, Jakesz R, Reiner G, Reiner A
Thymidine labeling index and Ki-67 growth fraction in breast cancer: Comparison and correlation with
prognosis
Breast Cancer Res Tr 1994; 32: 165-175
50
IF: 2,479
Fiegl M, Tueni C, Schenk T, Jakesz R, Gnant M, Reiner A, Rudas M, Pirc-Danoewinata H, Marosi C, Huber H, Drach J
Interphase cytogenetics reveals a high incidence of aneuploidy and intra-tumour heterogeneity in
breast cancer
Brit J Cancer 1995; 72: 51-55
51
IF: 3,449
Locker G, Simonitsch I, Mader RM, Warlamides E, Gnant M, Jakesz R, Rainer H, Steger G
Cutaneous Side Effects in breast cancer patients treated with cytostatic polychemotherapy and rh
GM-CSF: Immune henomena or drug toxicity ? (cutaneous reations to GM-CSF in breast cancer)
Breast Cancer Res Tr 1995; 34: 213-9
52
IF: 2,879
Jakesz R, Gnant M
Die Bedeutung der Lymphadenektomie bei Patienten mit colorectalem Carcinom
Acta Chir Aust 1995; 9: 99
53
IF: 0,000
Gnant M
Abdominalchirurgie in der geriatrischen Onkologie
Onko-logisch 1995; 3: 12-3
IF: 0,000
2
Univ. Prof. Dr. Michael Gnant
54
Originalarbeiten
-7-
Tschugguel W, Blaicher A, Klamer L, Felfernig M, Jungling G, Kurz M, Gnant M, Zimpfer M
Platelet disorders in uraemia before and after haemodialysis under the influence of low dose apirin
Thromb Res 1995; 80: 225-33
55
IF: 1,443
Gruenberger T, Gorlitzer M, Soliman T, Rudas M, Mittlboeck M, Goetzinger P, Gnant M, Reiner A, Teleky B, Seitz W,
Jakesz R
Kann man einer hochselektionierten Patientinnengruppe nach Brusterhaltender Therapie wegen
Mammakarzinoms die postoperative Nachbestrahlung ersparen?
Acta Chir Aust 1995; 27: 269-73
56
IF: 0,000
Berlakovich G, Imhof M, Karner-Hanusch J, Goetzinger P, Gollackner B, Gnant M, Hanelt S, Laufer G, Muehlbacher F,
Steininger R
The importance of the effect of underlying disease on rejection outcomes following orthotopic liver
transplantation
Transplantation 1996; 61: 554-60
57
IF: 3,544
Taucher S, Gnant M, Djavanmard M, Kandioler D, Goetzinger P, Rudas M, Steger G, Jakesz R
Neoadjuvant chemotherapy enables breast conserving surgery in patients with very large breast
cancers
Onkologie 1996; 19: 242-6
58
IF: 0,451
Kandioler D, Dekan G, End A, Pasching E, Buchmayer H, Gnant M, Langmann F, Mannhalter C, Eckersberger F, Wolner E
Molecular genetic differentiation between primary lung cancers and lung metastases of other tumors
J Thorac Cardiov Surg 1996; 111: 827-31
59
IF: 2,874
Early Breast Cancer Trialists' Collaborative Group
Ovarian ablation in early breast cancer: overview of the randomised trials
Lancet 1996; 348: 1189-1196
60
IF: 17,948
Gruenberger T, Windhager T, Gnant M, Mittlboeck M, Steininger R, Herbst F, Muehlbacher F
Tumor recurrence after oLTX
Transplant Int 1996; 9S1: S151-4
61
IF: 1,522
Helbich T, Becherer A, Trattnig S, Leitha T, Kelkar P, Seifert, Gnant M, Staudenherz A, Rudas M, Wolf G, Mostbeck GH
Differentiation of benign and malignant breast lesions: MR imaging versus Tc-99m sestamibi
Scintimammography
Radiology 1997; 202: 421-9
62
IF: 4,698
Rudas M, Neumayer R, Gnant M, Mittlboeck, Jakesz R, Reiner A
p53 protein expression, cell proliferation and steroid hormone receptors in ductal and lobular in situ
carcinomas of the breast
Eur J Cancer 1997; 33: 39-44
IF: 2,743
2
Univ. Prof. Dr. Michael Gnant
63
Originalarbeiten
Jakesz R, Gnant M, Schmid M, Smonigg H, Steindorfer P, Hausmaninger H, Sevelda P, Depisch D, Tausch C, Reiner G,
Renner K, Stierer M, Pilz E, Jatzko G, Hofbauer F, Fridrik M, Schennach W, Dadak C, Haid A, Kusbista E, Scholz R,
Sagaster
P, Winter R,und
Lenzhofer
R laufende adjuvante Therapieprotokolle bei Patientinnen mit operablem
Abgeschlossene
derzeit
Mammakarzinom (II)
Acta Chirurgica Austriaca 1997; 29: 62-67
64
-8-
IF: 0,000
Steger G, Gnant M, Djavanmard M, Mader R, Jakesz R, Pierce W, deKernion J, Figlin R, Belldegrun A
The in vitro effects of interleukin-12 upon tumor-infiltrating lymphocytes derived from renal cell
carcinoma
J Cancer Res Clin Oncol 1997; 123: 317-324
65
IF: 1,459
Müller M, Mader RM, Steiner B, Steger GG, Jansen B, Gnant M, Helbich T, Jakesz R, Eichler HG, Blöchl-Daum B
5-fluorouracil kinetics in the interstital tumor space: clinical response in breast cancer patients
Cancer Res 1997; 57: 2598-601
66
IF: 8,426
Reiner A, Rudas M, Neumayer R, Gnant M, Mittlboeck M, Jakesz R
Protein-p53-Expression, Cell proliferation and steroid hormone receptors in Ductal Carcinoma in situ
of the breast
Acta Chir Aust 1997; 29: 123-125
67
IF: 0,000
Gruenberger T, Gorlitzer M, Soliman T, Rudas M, Mittlboeck M, Gnant M, Reiner A, Teleky B, Seitz W, Jakesz R
It is possible to omit postoperative irradiation in a highly selected group of elderly breast cancer
patients?
Breast Cancer Res Tr 1998; 50: 37-46
68
IF: 2,430
Helbich T, Rudas M, Haitel A, Kohlberger P, Thurnher M, Gnant M, Wunderbaldinger P, Wolf G, Mostbeck G
Evaluation of needle size for breast biopsy: Comparison of 14-, 16, and 18-gauge biopsy needles
Am J Roentgenol 1998; 171: 59-63
69
IF: 2,332
Jakesz R, Samonigg H, Gnant M, Kubista E, Steindorfer P, Hausmaninger H, Sevelda P, Tschurtschenthaler B, Fridrik M,
Stierer M, Kolb R, Steger G, and the Austrian Breast Cancer Study Group
Very low dose adjuvant chemotherapy in steroid receptor negative stage I breast cancer patients
Eur J Cancer 1998; 34:66-70
70
IF: 2,743
Early Breast Cancer Trialists' Collaborative Group
Tamoxifen for early breast cancer: an overview of the randomised trials
The Lancet 1998; 351: 1451-1467
71
IF: 16,135
Peck-Radosavljevic M, Pidlich J, Bergmann M, Ferenci P, Seelos C, Wichlas M, Lipinski E, Gnant M, Gangl A, Muehlbacher
F and the Liver Transplant Oncology Group
Preoperative TNM-classification is a better prognostic indicator for recurrence of hepatocellular
carcinoma after liver transplantation then albumin mRNA in peripheral blood
J Hepatol 1998; 28: 497-503
IF: 3,189
2
Univ. Prof. Dr. Michael Gnant
72
Originalarbeiten
-9-
Cosentini E, Sautner T, Gnant M, Winkelbauer F, Teleky B, Jakesz R
Outcomes of surgical, Percutaneous endoscopic, and percutaneous radiologic gastrostomies
Arch Surg 1998; 133: 1076-1083
73
IF: 2,526
Wu P, Berger A, Huang J, Gnant M, Turner E, Alexander HR, Libutti S
In vivo tumors that overexpress Endothelial Monocyte-Activatin Polypeptide II demonstrate
upregulation of tumor necrosis factor receptor p55 on tumor neovasculature
Surg Forum 1998; 49: 436-438
74
IF: 0,000
Early Breast Cancer Trialists' Collaborative Group
Polychemotherapy for early breast cancer: an overview of the randomised trials
The Lancet 1998; 351: 1451-1467
75
IF: 11,793
Jakesz R, Taucher S, Gnant M, Gebhard B, Kandioler D, Rudas M, Djavanmard M, Steger G
Neoadjuvante Chemotherapie bei Patientinnen mit Mammakarzinom
Zentralbl Chir 1998; 123 (S5) 147-150
76
IF: 0,425
Götzinger P, Gebhard B, Gnant M, Rudas M, Reiner A, Jakesz R
Die Wertigkeit der Stanzbiopsie in der Diagnostik palpabler Brusttumoren. Eine prospektive Analyse
an 150 Patienten.
Chirurg 1998; 69: 1068-71
77
IF: 0,932
Friedl J, Stift A, Berlakovich G, Taucher S, Gnant M, Steininger R, Mühlbacher F
Haemophilus parainfluenza liver abscess after successful liver transplantation
J Clin Microbiol 1998: 818-9
78
IF: 3,579
Pokorny H, Puhalla H, Krenn CG, Soliman T, Langer F, Gruenberger T, Gollackner B, Schindl M, Wamser P, Goetzinger P,
Sautner T, Gnant M, Steininger R, Muehlbacher F
Management of organ donation following trauma in conventional heart-beating donor and non-heartbeating donor situations
Trauma Care 1999; 9: 30-32
79
IF: 0,000
Locker GJ, Steger GG, Gnant M, Steiner B, Simonitsch I, Krainer M, Budinsky A, Brodowitz T, Jakesz R, Zielinski CC
Induction of Immunomediated Diseases by Recombinant Human Granulocyte-Macrophage ColonyStimulating Factor During Cancer Treatment?
J Immunotherapy 1999; 22: 85-9
80
IF: 3,059
Gnant M, Puhlmann M, Alexander HR, Bartlett DL
Systemic Administration of a Recombinant Vaccinia Virus Expressing the Cytosine Deaminase Gene
and Subsequent Treatment with 5-Fluorocytosine Leads to Tumor-specific Gene Expression and
Prolongation
of Survival
in Mice
Cancer
Res 1999;
59: 3396-3403
IF: 8,614
2
Univ. Prof. Dr. Michael Gnant
81
Originalarbeiten
- 10 -
Jakesz R, Gebhard B, Gnant M, Taucher S
Indikationen und Kontraindikationen für brusterhaltende chirurgische Therapie
Chirurg 1999; 70: 394-399
82
IF: 0,932
Gnant M, Puhlmann M, Bartlett DL, Alexander HR
Regional versus Systemic Delivery of Recombinant Vaccinia Virus as Suicide Gene Therapy for
Murine Liver Metastases
Ann Surg 1999; 230: 352-361
83
IF: 5,987
Wenzel C, Schmidinger M, Locker GJ, Taucher S, Gnant M, Jakesz R, Steger GG
Clinical phase II-evaluation of neoadjuvant, cytostatic combination chemotherapy with docetaxel and
epidoxorubicin in female breast cancer patients (T1-4, N0-2, M0)
Wien Klin Wochenschr 1999; 111: 843-850
84
IF: 0,588
Puhlmann M, Gnant M, Brown C, Alexander H, Bartlett D
Thymidine kinase-Deleted Vaccinia Virus Expressing Purine Nucleoside Phosphorylase as a Vector
for Tumor-Directed Gene Therapy
Hum Gene Ther 1999; 10: 649-657
85
IF: 6,796
Kucera E, Speiser P, Gnant M, Szabo L, Samonigg H, Hausmaninger H, Mittlboeck M, Fridrik M, Seifert M, Kubista E,
Reiner A, Zeillinger R, Jakesz R, and the ABCSG
Prognostic significance of mutations in the p53 gene, particularly in the Zinc-binding domains, in
lymph node- and steroid receptor positive breast cancer patients
Eur J Cancer 1999; 35: 398-405
86
IF: 2,725
Gnant M, Noll L, Irvine K, Puhlmann M, Terrill R, Alexander R, Bartlett D
Tumor-specific gene delivery using recombinant vaccinia virus in a lapine model of liver metastases
J Nat Cancer Inst 1999; 91:1744-50
87
IF: 14,159
Jakesz R, Hausmaninger H, Haider K, Kubista E, Samonigg H, Gnant M, Manfreda D, Tschurtschenthaler G, Kolb R,
Stierer M, Fridrik M, Mlineritsch B, Mittlboeck M, Steger G, and the Austrian Breast Cancer Study Group
Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and
lymph node-positive breast cancer
J Clin Oncol 1999; 17: 1701-1709
88
IF: 8,773
Gnant M, Noll LA, Terrill RE, Wu PC, Berger AC, Nguyen HQ, Lans TE, Flynn BM, Libutti SK, Bartlett DL, Alexander HR
Isolated hepatic perfusion for lapine liver metastases: Impact of hyperthermia on permeability of
tumor neovasculature
Surgery 1999; 126: 890-899
89
IF: 2,456
Wu P, Alexander H, Huang J, Hwu P, Gnant M, Berger A, Turner E, Wilson O, Libutti S
In vivo sensitivity of human melanoma to tumor necrosis factor (TNF) alpha is determined by tumor
production of the novel cytokine Endothelial-Monocyte Activating Polypeptide II (EMAPII)
Cancer Res 1999; 59: 205-12
IF: 8,614
2
Univ. Prof. Dr. Michael Gnant
90
Originalarbeiten
- 11 -
Gnant M, Berger A, Huang J, Puhlmann M, Wu P, Merino M, Bartlett D, Alexander R, Libutti S
Sensitiziation of tumor necrosis factor alpha (TNF) resistant human melanoma by tumor specific in
vivo transfer of the gene endcoding for Endothelial Monocyte Activating Peptide II (EMAP-II) using
recombinant
Vaccinia
virus
Cancer
Res 1999;
59:4668-74
IF: 8,614
91
Gnant M
Highlights vom ASCO 99 - Mammakarzinom adjuvant
Onkologisch 1999; 7: 9-11
92
IF: 0,000
Gebhard B, Schuetz G, Ecker R, Steiner GE, Rudas M, Gnant M, Oehler R
Class I major histocompatibiliy complex expression in human breast cancer correlates with nuclear
localization of the 90 kDa heat shock protein
Anticancer Res 1999; 19: 5293-5297
93
IF: 1,375
Gnant M, Turner E, Alexander HR
Effects of hyperthermia and tumor necrosis factor on inflammatory cytokine secretion and
procoagulant activity in endocelial cells
Cytokine 2000; 12; 339-347
94
IF: 2,490
Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C, Schlagbauer-Wadl H, Mittlboeck M,
Gnant M, Steger G, Jakesz R
TP53 Mutation and p53 Overexpression for Prediction of Response to Neoadjuvant Treatment in
Breast Cancer Patients
Clin Cancer Res 2000; 6: 50-56
95
IF: 5,076
Puhlmann M, Brown C, Gnant M, Huang J, Libutti S, Alexander H, Bartlett D
Vaccinia as a vector for tumor directed gene therapy: Biodistribution of a thymidine kinase deleted
mutant
Cancer Gene Ther 2000; 7: 66-73
96
IF: 4,151
Bachleitner-Hofmann T, Gnant M
Die chirurgische Axilladissektion: Technischer Standard oder obsolete Methode?
Zbl Chir 2000; 125: 822-829
97
IF: 0,302
Berger AC, Feldman AL, Gnant M, Kruger EA, Sim BKL, Hewitt S, Figg WD, Alexander HR, Libutti SK
The angiogenesis inhibitor Endostatin does not affect murine cutaneous wound healing
J Surg Res 2000; 91: 26-31
98
IF: 1,674
Early Breast Cancer Trialists' Collaborative Group
Favourable and unfavourable effects on long-term survival of radiotherapy for eraly breast cancer: an
overview of the randomised trials
Lancet 2000; 355:1757-1770
IF: 13,251
2
Univ. Prof. Dr. Michael Gnant
99
Originalarbeiten
- 12 -
Bachleitner-Hofmann T, Gnant M
Die axilläre Lymphknotendissektion in der Therapie des Mammakarzinoms
Acta Chirurgica Austriaca 2000; 32: 119-123
100
IF: 0,000
Stift A, Friedl J, Brostjan C, Dubsky P, Schueller G, Bachleitner-Hofmann T, Radelbauer K, Jakesz R, Gnant M
Adoptive zelluläre Immuntherapie
Acta Chirurgica Austriaca 2000; 32:255-259
101
IF: 0,000
Berger AC, Alexander HR, Wu PC, Tang G, Gnant M, Mixon A, Turner E, Libutti SK
Tumor necrosis factor receptor I (p55) is upregulated on endothelial cells by exposure to the tumor
derived cytokine endothelial monocyte activating peptide II (EMAP-II)
Cytokine 2000; 12:992-1000
102
IF: 2,490
Friedl J, Stift A, Paolini P, Roth E, Steger GG, Mader R, Jakesz R, Gnant M
Tumor antigen pulsed dendritic cells enhance the cytolytic activity of tumor infiltrating lymphocytes in
human hepatocellular cancer
Cancer Biother Radio 2000; 15: 477-86
103
IF: 1,574
Bachleitner-Hofmann T, Gnant M
Gentherapie - Tor zur Zukunft?
Acta Chirurgica Austriaca 2000; 32: 264-269
104
IF: 0,000
Lans TE, Bartlett DL, Libutti SK, Gnant M, Liewehr DJ, Venzon DJ, Turner EM, Alexander HR
Role of Tumor Necrosis Factor (TNF) on Toxicity and Cytokine Production after Isolated Hepatic
Perfusion
Clin Cancer Res 2001; 7: 784-790
105
IF: 5,991
Gnant M
Chirurgische Onkologie an der Jahrtausendwende - Editorial
Acta Chirurgica Austriaca 2000; 32: 249-250
106
IF: 0,000
Gebhard B, Gnant M, Schutz G, Roka S, Weigel G, Kandioler D, Taucher S, Grunberger T, Roth E, Jakesz R, Spittler A
Different transendothelial migration behaviour pattern of blood monocytes derived from patients with
benign and malignant diseases of the breast
Anticancer Res 2000; 4599-604
107
IF: 1,416
Schueller G, Paolini P, Friedl J, Stift A, Dubsky P, Bachleitner-Hofmann T, Jakesz R, Gnant M
Heat Treatment of Hepatocellular Carcinoma Cells: Increased Levels of Heat Shock Proteins 70 and
90 Correlate with Cellular Necrosis
Anticancer Res 2001; 21: 295-300
IF: 1,416
2
Univ. Prof. Dr. Michael Gnant
108
Originalarbeiten
- 13 -
Locker GJ, Wenzel C, Schmidinger M, Gnant M, Marosi C, Jakesz R, Zielinski CC, Steger G
Unexpected severe myelotoxicity of gemcitabine in pretreated breast cancer patients
Anticancer Drugs 2001; 12: 209-12
109
IF: 2,013
Birner P, Oberhuber G, Stani J, Reithofer C, Samonigg H, Hausmaninger H, Kubista E, Kwasny W, Kandioler-Eckersberger
D, Gnant M, Jakesz R
Evaluation of the United States food and drug administration-approved scoring and test system of
HER-2 protein expression in breast cancer
Clin Cancer Res 2001; 7: 1669-1675
110
IF: 5,991
Janschek E, Kandioler-Eckersberger D, Ludwig C, Kappel S, Wolf B, Taucher S, Rudas M, Gnant M, Jakesz R
Contralateral breast cancer: molecular differentiation between metastasis and second primary cancer
Br Cancer Res Treat 2001; 67:1-8
111
IF: 2,866
Latinovic L, Heinze G, Birner P, Samonigg H, Hausmaninger H, Kubista E, Kwasny W, Gnant M, Jakesz R, Oberhuber G,
for the Austrian Breast and Colorectal Cancer Study Group
Prognostic Relevance of three histological grading methods in breast cancer
Int J Oncol 2001; 19: 1271-1277
112
IF: 2,330
Schmidinger M, Wenzel C, Locker GJ, Muehlbacher F, Steininger R, Gnant M, Crevenna R, Budinsky AC
Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular
carcinoma
Br J Cancer 2001; 85: 1850-1852
113
IF: 3,942
Cole BF, Gelber RD, Gelber S, Coates AS, Goldhirsch A, for the EBCTCG
Polychemotherapy for early breast cancer: an overview of the randomised trials with quality-adjusted
survival analysis
Lancet 1998; 358: 277-286
114
IF: 11,793
Wenzel C, Locker GJ, Schmidinger M, Rudas M, Taucher S, Gnant MFX, Jakesz R, Steger GG
Combined analysis of two phase II trials in patients wirh primary and advanced breast cancer with
epidoxorubicin and docetaxel + G-CSF
Anti-Cancer Drugs 2002; 13: 67-74
115
IF: 2,013
Bachleitner-Hofmann T, Stift A, Friedl J, Pfragner R, Radelbauer K, Dubsky P, Schueller G, Benkoe T, Niederle B, Brostjan
C, Jakesz R, Gnant M
Stimulation of autologous antitumor T-cell responses against medullary thyroid carcinoma using
tumor lysate-pulsed dendritic cells
J Clin Endoc Metab 2002; 87: 1098-1104
116
IF: 5,447
Wenzel C, Locker G, Pluschnig U, Zielinski C, Rudas M, Oberhuber G, Gnant M, Taucher S, Jakesz R, Steger G
Phase I/II trial of weekly epidoxorubicin and docetaxel (wED) in the neoadjuvant and palliative
treatment of patients with breast cancer
Cancer Chemother Pharmacol 2002; 50: 155-159
IF: 2,170
2
Univ. Prof. Dr. Michael Gnant
117
Originalarbeiten
- 14 -
Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, Jakesz R, Kubista E Birner P,
Oberhuber G
Overexpression of hypoxia inducible factor (HIF) 1alpha ias associated with an unfavourable
prognosis in lymph node-positive breast cancer
Clin Cancer Res 2002; 8: 1931-1837
IF: 5,991
118
Jakesz R, Hausmaninger H, Samonigg H, Kubista E, Gnant M, Menzel C, Bauernhofer T, Seifert M, Haider K, Steger G,
Mlineritsch B, Steindorfer P, Kwasny W, Fridrik M, Wette V, for the Austrian Breast Cancer Study Group
A Randomized Trial of Tamoxifen and Goserelin versus CMF: Evidence for the Superiority of
Treatment with Endocrine Blockade in Premenopausal Patients with Hormone-Responsive Breast
(ABCSG
Trial1-9
5)
JCancer
Clin Oncol
2002; 20:
IF: 9,868
119
Friedl J, Puhlmann M, Bartlett DL, Libutti SK, Turner EM, Gnant M, Alexander HR
Induction of permeability across endothelial cel monolayers by tumor necrosis factor (TNF) accurs via
a tue factor-dependent mechanism: relationship between the procoagulant and permeability effects of
TNF.
Blood 2002; 100: 1334-1339
IF: 9,631
120
Pfarl G, Helbich TH, Riedl CC, Wagner T, Gnant M, Rudas M, Liberman L
Stereotactic 11-gauge vacuum assisted breast biopsy: a validation study
AJR 2002; 179: 1503-1507
121
IF: 2,424
Bachleitner-Hofmann T, Gebhard B, Rudas M, Gnant M, Taucher S, Kandioler D, Janschek E, Dubsky P, Roka S, Jakesz
R
Pattern of hormone receptor status of secondary contralateral breast cancers in patients receiving
adjuvant tamoxifen
Clin Cancer Res 2002; 8: 3427-3432
122
IF: 5,991
Dubsky PC, Gnant M, Taucher S, Roka S, Kandioler D, Pichler-Gebhard B, Agstner I, Seifert M, Sevelda P, Jakesz R
Young age as independent adverse prognostic factor in premenopausal patients with breast cancer
Clin Breast Cancer 2002; 13: 67-74
123
IF: 0,000
Stift A, Friedl J, Brostjan C, Dubsky P, Bachleitner-Hofmann T, Jakesz R, Gnant M
Dendritic cell based vaccination in solid organ cancer
J Clin Oncol 2003; 21: 135-142
124
IF: 10,864
Taucher S, Rudas M, Gnant M, Dubsky P, Roka S, Bachleitner-Hofmann T, Kandioler D, Wenzel C, Steger G, Mittlboeck
M, Jakesz R
Sequential steroid hormone receptor measurements in primary breast cancer with and without
intervening primary chemotherapy
Endo Rel Cancer 2003; 10: 91-98
125
IF: 8,894
Stift A, Friedl J, Dubsky P, Bachleitner-Hofmann T, Benkoe T, Brostjan C, Jakesz R, Gnant M
In vivo induction of dendritic cell-mediated cytotoxicity against allogeneic pancreatic carcinoma cells
Int J Oncol 2003; 22: 651-660
IF: 2,536
2
Univ. Prof. Dr. Michael Gnant
Originalarbeiten
- 15 -
126
Schmid M, Jakesz R, Samonigg H, Kubista E, Gnant M, Menzel C, Seifert M, Haider K, Taucher S, Mlineritsch B,
Steindorfer P, Kwasny W, Fridrik M, wette H, Hausmaninger H, for the Austrian Breast Cancer Study Group
Tamoxifen versus Tamoxifen plus Aminoglutethimid as Adjuvant Treatment in Postmenopausal
breast Cancer Patients wirth Hormone-responsive Disease: A Randomized Trial of 2,021 Patients
Trial
6) 21: 984-990
J(ABCSG
Clin Oncol
2003;
IF: 10,864
127
Schoppmann S, Schindl M, Bayer G, Aumayr K, Dienes J, Horvat R, Rudas M, Gnant M, Jakesz R, Birner
Overexpression of Id-1 is associated with poor clinical outcome in node negative breast cancer
Int J Cancer 2003; 104: 677-682
128
IF: 4,375
Schueller G, Stift A, Friedl J, Dugsky P, Bachleitner-Hofmann T, Benkoe T, Jakesz R, Gnant M
Hyperthermia improves cellular immune response to human hepatocellular carcinoma subsequent fo
co-culture with tumor lysate pulsed dendritic cells
Int J Oncol 2003; 22: 1397-1402
129
IF: 2,536
Taucher S, Salat A, Gnant M, Kwasny W, Mlineritsch B, Menzel RC, Schmid M, Smola MG, Stierer M, Tausch C, Galid A,
Jakesz R, for the Austrian Breast and colorectal Cancer Study Group
Impact of pretreatment thrombocytosis on survival in primary breast cancer
Thromb Haemost 2003; 89: 1098-1106
130
IF: 4,950
Heinze G, Gnant M, Schemper M
Exact log rank tests for unequal follow-up
Biometrics 2003; 59: 1151-1157
131
IF: 1,324
Taucher S, Gnant M, Jakesz R
Preventive mastectomy in patients at breast cancer risk due to genetic alterations in the BRCA1 and
BRCA2 gene
Langenbecks Arch Surg 2003; 388: 3-8
132
IF: 0,921
Ploner F, Jakesz R, Hausmaninger H, Kolb R, Stierer M, Fridrik M, Steindorfer P, Gnant M, Haider K, Mlineritsch B,
Tschurtschenthaler G, Steger G, Seifert M, Kubista E, Samonigg H, and the Austrian Breast and Colorectal Cancer Study
Group
Randomized trial: One cyle of anthracycline-containing adjuvant chemotherapy compared with six
cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients
Onkologie 2003: 26: 115-119
133
IF: 1,154
Future Directions in the treatment of Breast Cancer: Celllular interventions using dendritic cells
Gnant M, Dubsky P, Stift A, Friedl J, Steger G, Jakesz R, Zielinski C
Breast Canc Res Treatm 2003; 81
134
IF: 3,310
Brostjan C, Bayer A, Zommer A, Gornikiewicz S, Roka S, Benkö T, Yaghubian R, Jakesz R, Steger G, Gnant M, Friedl J,
Stift A
Monitoring of circulating angiogenetic factors in dendritic cell-based cancer immunotherapy
Cancer 2003; 98: 2291-30
IF: 4,017
2
Univ. Prof. Dr. Michael Gnant
135
Originalarbeiten
Taucher S, Rudas M, Gnant M, Dubsky P, Sporn E, Roka S, Bachleitner-Hofmann T, Fitzal F, Kandioler D, Wenzel C,
Steger G, Draxler W, Mittlboeck M, Jakesz R
The impact of progesterone receptor in prediction of complete pathological response to preoperative
chemotherapy in primary breast cancer patients
European Surgery 2003;
136
- 16 -
IF: 0,000
Gnant M
Pancreatic Cancer Treatment
European Surgery 2003; 35: 342-343
137
IF: 0,000
Taucher S, Rudas M, Mader R, Gnant M, Dubsky P, Bachleitner-Hofmann T, Roka S, Fitzal F, Kandioler D, Sporn E, Friedl
J, Mittlboeck M, Jakesz R
Do we need HER2/neu testing for all patients with primary breast carcinoma?
Cancer 2003; 98: 2547-2553
138
IF: 4,017
Beslija S, Bonneterre J, Burstein H, Gnant M, Goodwin P, Heinemann V, Jassem J, Köstler W, Krainer M, Menard S, Miles
D, Petruzelka L, Possinger K, Schmid P, Stadtmauer E, Stockler M, Van Belle S, Vogel C, Wilcken N, Wiltschke C, Zielinski
C,
Zwierzina Hon Medical Treatment of Metastatic Breast Cancer
Consensus
Br Canc Res Treatm 2003; 81: S1-S7
139
IF: 2,964
Taucher S, Rudas M, Mader R, Gnant M, Sporn E, Dubsky P, Roka S, Bachleitner-Hofmann T, Fitzal F, Kandioler D,
Wenzel C, Steger G, Mittlboeck M, Jakesz R
Influence of neoadjuvant therapy with epirubicin an ddocetaxel on the expression of HER2/neu in
patients with breast cancer
Breast Canc Res Treatm 2003; 82: 207-213
140
IF: 2,964
Jakesz R, Hausmaninger H, Samonigg H, Gnant M, Kubista E, Depisch D, Kolb R, Mlineritsch B, Mischinger HJ, Menzel
RC, Steindorfer P, Kwasny W, Tausch C, Stierer M, Seifert M, and the Austrian Breast & Colorectal Cancer Study Group
(ABCSG)
Significant Increase in breast conservation in 16 years of clinical trials conducted by the Austrian
Breast & Colorectal Cancer Study Group
Ann Surg 2003; 237: 556-564
141
IF: 6,664
Schueller G, Kettenbach J, Sedivy R, Stift A, Friedl J, Gnant M, Lammer J
Heat shock protein expression induced by percutaneous radiofrequency ablation of hepatocellular
carcinoma in vivo
Int J Oncol 2004; 24:609-13
142
IF: 3,056
Stift A, Friedl J, Gnant M, Herbst F, Jakesz R, Wenzl E
Gastrointestinal Autonomic Nerve Tumors: A surgical point of view
World J Gastroenterology 2004; 10: 2447-2451
143
IF: 3,318
Schoppmann S, Bayer G, Aumayr K, Taucher S, Geleff S, Rudas M, Kubista E, Hausmaninger H, Samonigg H, Gnant M,
Jakesz R, Horvat R, and the Austrian Breast and colorectal Cancer Study Group
Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer
Annals Surg 2004; 204: 306-312
IF: 5,907
2
Univ. Prof. Dr. Michael Gnant
144
Originalarbeiten
- 17 -
Stift A, Sachet M, Yagubian R, Bittermann C, Dubsky P, Pfragner R, Niederle B, Jakesz R, Gnant M, Friedl J
Dendritic cell vaccination in medullary thyroid carcinoma
Clin Cancer Res 2004; 10:2944-2953
145
IF: 5,623
Taucher S, Rudas M, Mader R, Gnant M, Dubsky P, Roka S, Bachleitner-Hofmann T, Kandioler D, Steger G, Mittlboeck M,
Jakesz R
Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325
primary breast cancer patients
Wien Klin Wochenschr 2004; 116:26-31
146
IF: 0,901
Wenzel C, Hussian D, Bartsch R, Pluschnig U, Locker GJ, Rudas M, Gnant M, Jakesz R, Zielinski C, Steger G
Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary
breast cancer: a pilot study
J Cancer Res Clin Oncol 2004; 130: 400-404
147
IF: 2,409
Schueller G, Kettenbach J, Sedivy R, Bergmeister H, Stift A, Friedl J, Gnant M, Lammer J
Expression of heat shock proteins in human hepatocellular carcinoma after radiofrequency ablation in
an animal model
Oncology Rep 2004; 12: 495-499
148
IF: 1,356
Roka S, Rudas M, Taucher S, Dubsky P, Bachleitner-Hofmann T, Kandioler D, Gnant M, Jakesz R
High nuclear grade and negative estrogen receptor are significant risk factors for recurrence in DCIS
Eur J Surg Oncol 2004; 30; 243-247
149
IF: 1,882
Schippinger W, Jagoditsch M, Sorre C, Gnant M, Steger G, Hausmaninger H, Mlineritsch B, Schaberl-Moser R, Mischinger
HJ, Hofbauer F, Holzberger P, Mittlböck M, Jakesz R, for the ABCSG
A prospective randomized trial to study the role of levamisole and interferon alfa in an adjuvant
theapy with 5-FU for stage-III colon cancer
Br J Cancer 2005; 92: 1655-62
150
IF: 4,115
Early Breast Cancer Trialists Collaborative Group (EBCTCG)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year
survival: an overview of the randomised trials
Lancet 2005; 365: 1687-1717
151
IF: 23,878
Pokorny H, Gnant M, Rasoul-Rockenschaub S, Gollackner B, Steiner B, Steger G, Steininger R, Muehlbacher F
Does additional doxorubicin chemotherapy improve outcome in patients with hepatocellular
carcinoma treated by liver transplantation?
Am J Transplant 2005; 5: 788-94
152
IF: 6,002
Wenzel C, Bartsch R, Locker GH, Hussian D, Pluschnig D, Sevelda U, Gnant M, Jakesz R, Zielinski C, Steger GG
Preoperative chemotherapy with epidoxorubicin, docetaxel, and capecitabine plus pegfilgrastim in
patients with primary breast cancer
Anticancer Drugs 2005; 16: 441-5
IF: 2,052
2
Univ. Prof. Dr. Michael Gnant
153
Originalarbeiten
- 18 -
Pfragner R, Skofitsch G, Hoger H, Jech M, Rinner B, Siegl V, Niederle B, Gnant M, Friedl J, Stift A
Medullary thyroid carcinoma: autologous tumor cell lins for dendritic cell vaccination
Anticancer Res 2005; 25:4225-30
154
IF: 1,604
Gornikiewicz A, Zommer A, Jakesz R, Gnant M, Brostjan C
Retroviral targeting of proliferating endothelial cells
Acta Biochim Pol 2005; 52: 731-5
155
IF: 1,863
Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M,
Gademann G, Kaufmann M, for the ABCSG and the GABG
Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole
after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial
Lancet 2005; 366: 455-62
156
IF: 23,887
Dubsky P, Friedl J, Stift A, Bachleitner-Hofmann T, Jakesz R, Gnant M, Weigel G
Inosine 5'-monophosphate dehydrogenase inhibition by mycophenolic acid impairs maturation and
function of dendritic cells
Clin Chim Acta 2006; 364: 139-47
157
IF: 2,328
Gnant M
Bisphosphonates and the prevention of osteoporosis in the adjuvant setting
Breast Cancer Online 2005; Nov; 1-3, e55
158
IF: 0,000
Piccart-Gebhart M, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C,
Cameron D, Dowsett M, Barrios C, Steger G, Huang C, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H,
Thomssen
C, Lohrisch
C, Suter T, chemotherapy
Rüschoff J, Sütö T,
V, Ward breast
C, Straehle
C, McFadden E, Dolci M, Gelber R,
Trastuzumab
after adjuvant
inGreatorex
HER2-positive
cancer
N Eng J Med 2005; 353: 1659-72
159
IF: 44,016
Steger G, Bartsch R, Wenzel C, Pluschnig U, Hussian D, Sevelda U, Locker G, Gnant M, Jakesz R, Zielinski C
Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: a single-center
experience
Eur J Cancer 2005; 41: 2655-61
160
IF: 3,706
Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S, MacKinnon E,
McGale P, McHugh T, Peto R, Taylor C, Wang Y and the Early Breast Cancer Trialists Collaborative Group (EBCTCG)
Effects of radiotherapy and of differences in the extend of surgery for early breast cancer on local
recurrence and on 15-year survival: an overview of the randomised trials
Lancet 2005; 366: 2087-106
161
IF: 23,878
Wenzel C, Locker G, Bartsch R, Pluschnig U, Hussian D, Zielinski CC, Rudas M, Gnant M, Jakesz R, Steger GG
Preoperative second-line chemotherapy induces objective responses in primary breast cancer
Wien Klin Wochenschr 2005; 117: 48-52
IF: 0,901
2
Univ. Prof. Dr. Michael Gnant
162
Originalarbeiten
- 19 -
Fitzal F, Sporn E, Draxler W, Mittlboeck M, Taucher S, Rudas M, Roedl O, Helbich T, Jakesz R, Gnant M
Preoperative core needle biopsy does not increase local recurrence rate in breast cancer patients
Breast Cancer Res Treatm 2006; 97: 9-15
163
IF: 4,671
Ausch C, Maddoff RD, Gnant M, Rosen HR, Garcia-Aguilar J, Hoelbling N, Herbst F, Buxhofer V, Holzer B, Rothenberger
DA, Schiessel R
Aetiology and surgical management of toxic megacolon
Int J Colorectal Disease 2006; 8: 195-201
164
IF: 2,006
Gnant M
Surgical Oncology - a proud speciality
European Surgery 2006; 38/1: 2-3
165
IF: 0,000
Dubsky P, Gnant M
The endocrine origin and different characters of breast cancers - recent research on hormone
receptors and endocrine treatment
Breast Care 2006; 1: 124-8
166
IF: 0,242
Schoppmann S, Fenzl A, Nagy K, Unger S, Bayer G, Geleff S, Gnant M, Horvath R, Jakesz R, Birner P
VEGF-C expressing tumor-associated macrophages in lymph node positive breast cancer: impact on
lymphangiogenesis and survival
Surgery 2006; 139: 839-46
167
IF: 2,977
Gnant M
Management of bone loss induced by aromatase inhibitors
Cancer Invest 2006; 24: 328-30
168
IF: 2,335
Schoppmann SF, Fenzl A, Schindl M, Bachleitner-Hofmann T, Nagy K, Gnant M, Horvat R, Jakesz R, Birner P
Hypoxia inducible factor-1alpha correlates with VEGF-C expression and lymphangiogenesis in breast
cancer
Breast Cancer Res Treat 2006; 99: 135-41
169
IF: 4,671
Fitzal F, Gnant M
Breast conservation: evolution of surgical strategies
Breast 2006; 12S2: 165-73
170
IF: 1,705
Gnant M
Breast Centers Revisited - a critical perspective
Breast Care 2006; 1: 150-1
IF: 0,242
2
Univ. Prof. Dr. Michael Gnant
171
Originalarbeiten
- 20 -
Schueller G, Schima W, Schueller-Weidekamm C, Weber M, Stift A, Gnant M, Prokesch R
Multidetector CT of Pancreas_ Effects of Contrast Material Flow Rate and Individualized Scan Delay
on Enhancement of Pancreas and Tumor Contrast
Radiology 2006; 241: 441-8
172
IF: 5,251
Gnant M, Jonat W, Boccardo F, Kaufmann M, Rubagotti A, Zuna I, Greenwood M, Jakesz R
Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with
hormone-sensitive early-stage breast cancer: a meta-analysis
Lancet Oncology 2006; 7: 991-996
173
IF: 10,119
Bachleitner-Hofmann T, Strohschneider M, Krieger P, Sachet M, Dubsky P, Hayden H, Schoppmann S, Pfragner R, Gnant
M, Friedl J, Stift A
Heat shock treatment of tumor lysat-pusled DCs enhances their capacity to elicit antitumor T-cell
responses against medullary thyroid carcinoma
J Clin Endocrinol Metab 2006; 91: 4571-7
174
IF: 5,799
Gnant M, Blaha P
Breast Cancer Chemoprevention - not yet there
Breast Care 2006; 1: 295-6
175
IF: 0,242
Bachleitner-Hofmann T, Schoppmann S, Rudas M, Birner P, Wiener H, Dubsky P, Blaha P, Sporn E, Panhofer P, Fitzal F,
Roka S, Kandioler D, Gnant M, Jakesz R
A case of phylloides tumor with focal transition into low-grade lymphangiosarcoma
Breast Care 2006; 1: 391-4
176
IF: 0,242
Wenzel C, Bartsch R, Hussian D, Pluschnig U, Altoraj G, Zielinski CC, Lang A, Hais A, Jakesz R, Gnant M, Steger G
Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following
neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF
Br Canc Res Treat 2007; 104: 109-14
177
IF: 4,453
Fitzal F, Riedl O, Wutzl L, Draxler W, Rudas M, Pluschnig U, Handl-Zeller L, Dubsky P, Bachleitner-Hofmann T, Steger G,
Jakesz R, Gnant M
Breast conserving surgery for T3/T4 breast cancer: an analysis of 196 patients
Breast Cancer Res Treatm 2007; 103: 45-52
178
IF: 4,453
Beslija S, Bonneterre J, Bustein H, Cocquyt V, Gnant M, Goodwin P, Heinemann V, Jassem J, Köstler WJ, Krainer M,
Menard S, Miles D, Petit T, Petruzelka L, Possinger K, Schmid P, Stadtmauer E, Stockler M, Van Belle S, Vogel C, Wilcken
N,
Wiltschke
C, Zielinski on
C, Zwierzina
Second
Consensus
MedicalHTreatment of Metastatic Breast Cancer
Ann Oncol 2007; 18:215-25
179
IF: 4,875
Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Grampp S, Kaessmann H, Schmid M, Menzel C, Piswanger-Soelkner JC,
Galid A, Mittlboeck M, Hausmaninger H, Jakesz R, and the ABCSG
Zoledronic Acid effectively prevents Cancer treatment-induced bone loss in premnopausal women
receiving adjuvant andocrine therapy for hormone responsive breast cancer
J Clin Oncol 2007; 25: 820-8
IF: 15,484
2
Univ. Prof. Dr. Michael Gnant
180
Originalarbeiten
Steger GG, Galid A, Gnant M, Mlineritsch B, Lang A, Tausch C, Rudas M, Greil R, Wenzel C, Singer C, Haid A,
Poestlberger S, Samonigg H, Luschin-Ebengreuth G, Kwasny W, Klug E, Kubista E, Menzel C, Jakesz R, and the ABCSG
Pathologic complete response with 6 vs. 3 cycles oof Neoadjuvant epirubicin/decetaxel + G-CSF in
operable breast cancer: resutls of ABCSG-14
J Clin Oncol 2007; 25: 2012-8
181
IF: 15,678
Fitzal F, Krois W, Trischler H, Wutzel L, Riedl O, Kühbelböck U, Wintersteiner B, Cardoso MJ, Dubsky P, Gnant M, Jakesz
R, Wild T
The use of a breast symmetry index for objective evaluation of breast
cosmesis
Breast 2007;4:429-35
182
- 21 -
IF: 1,739
Schindl M, Gnant M, Schoppmann S, Horvat R, Birner P
Overexpression of the human homologue for Caenorhabditis elegans cul-4 gene is associated with
poor outcome in node-negative breast cancer
Anticancer Res 2007; 27: 949-52
183
IF: 1,414
Lipton A, Gnant M, Aapro M
Managing aromatase inhibitor-associated bone loss in breast cancer
Womans Health 2007; 3:441-448
184
IF: 0,000
Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, Mlineritsch B, Tausch C, Stierer M, Hofbauer F, Renner K,
Dadak C, Ruecklinger E, Samonigg H, on behalf of the ABCSG
Extended adjuvant therapy with Anastrozole among postmenopausal breast cancer patients: Results
from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a
J Natl Canc Inst 2007; 99:1845-53
185
IF: 15,678
LHRH-agonists in Early Breast Cancer Overview Group
Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal
patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from
randomised
adjuvant
trials
Lancet
2007; 369:
1711-23
IF: 28,638
186
Suter T, Procter M, van Veldhuisen D, Muscholl M, Bergh J, Carlomagno C, Perren T, Passalacqua R, Bighin C, Klijn J,
Ageev F, Hitre E, Groetz J, Iwata H, Knap M, Gnant M, Muehlbauer S, Spence A, Gelber R, Piccart-Gebhart M
Trastuzumab-associated cardiac adverse effects in the Herceptin Adjuvant trial
J Clin Oncol 2007; 25:3859-65
187
IF: 15,484
Poetter R, Gnant M, Kwasny W, Tausch C, Handl-Zeller L, Pakisch B, Taucher S, Hammer J, Luschin-Ebengreuth G,
Schmid M, Sedlmayer F, Stierer M, Reiner G, Kapp K, Hofbauer F, Rottenfusser A, Poestlberger S, Haider K, Draxler W,
Jakesz
R; on behaslf
the ABCSGor anastrozole with or without whole breast irradiation in women with
Lumpectomy
plusoftamoxifen
favourable early breast cancer
Int J Radiat Oncol 2007; 68: 334-40
188
IF: 4,290
Fitzal F, Nehrer G, Deutinger M, Jakesz R, Gnant M
Novel strategies in oncoplastic surgery for breast cancer: immediate partial reconstruction of breast
defects
Eur Surg 2007; 39:330-39
IF: 0,000
2
Univ. Prof. Dr. Michael Gnant
189
Originalarbeiten
- 22 -
Bartsch G, Wenzel C, Altoraj F, Pluschnig U, Rudas M, Mader R, Gnant M, Zielinski C, Steger G
Capecitabine and Trastuzumab in heavily preatreated patients with metastatic breast Cancer
J Clin Oncol 2007; 25: 3853-8
190
IF: 15,484
Fitzal F, Nehrer G, Hoch D, Riedl O, Gutharc S, Deutinger M, Jakesz R, Gnant M
An oncoplastic procedure for central and medio-cranial breast cancer
Eur J Surg Oncol 2007; 33: 1158-63
191
IF: 3,917
Bartsch T, Wenzel C, Altrofaj G, Pluschnig U, Mader R, Gnant M, Jakesz R, Rudas M, Zielinski C, Steger G
HER-2 and progesterone receptor are not predictive of response to fulvestrant treatment
Clin Cancer Res 2007; 13: 4435-9
192
IF: 6,250
Smith I, Procter M, Gelber R, Guillaume S, Teyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J,
Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardlay A, Harbeck N, Lopez R, Mallmann P, Gelmon K, Wilcken
N,
Wist E,
Rovira P, of
Piccart-Gebhart
M,after
for theadjuvant
HERA study
team
2-year
follow-up
trastuzumab
chemotherapy
in HER2-positive breast cancer: a
randomised controlled trial
Lancet 2007; 369: 29-36
193
IF: 28,638
Schippinger W, Samonigg H, Schaberl-Moser R, Greil R, Thodtmann R, Tschmelitsch J, Jagoditsch M, Steger G, Jakesz R,
Herbst F, Hofbauer F, Rabl H, Wohlmuth P, Gnant M, Thaler J, for the ABCSG
A prospective randomized phase III trial of adjuvant chemotherapy with 5-fuorouracil and leucovorin
in patients with stage II colon cancer
Br J Cancer 2007; 97(8):1021-7
194
IF: 4,635
Dubsky P, Hayder H, Sachet M, Bachleitner-Hofmann T, Hassler M, Pfragner R, Gnant M, Stift A, Friedl J
Allogenic tumor lysate can serve as both antigen source and protein supplementation for dendritic
cell culture
Cancer Immunol Immunother 2008;57(6):859-70
195
IF: 3,728
Taucher S, Steger G, Jakesz R, Tausch C, Wette V, Schippinger W, Kwasny W, Reiner G, Greil R, Bartsch R, Dubsky P,
Poestlberger S, Tschmelitsch J, Samonigg H, Gnant M
The potential risk of neoadjuvant chemotherapy in breast cancer patients - results from a prospective
randomised trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07)
Breast Cancer Res Treatm 2008; 112: 309-16
196
IF: 4,453
Aapro M, Abrahamsson P, Body J, Coleman R, Colomer R, Costa L, Crino L, Dirix L, Gnant M, Gralow J, Hadji P,
Hortobagyi G, Jonat W, Lipton A, Monnier A, Paterson A, Rizzoli R, Saad F, Thuerlimann B
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international
expert panel
Annals of Oncology 2008; 19: 420-32
197
IF: 4,875
Bartsch R, Welzel C, Gampenrieder S, Pluschnig U, Altoraj G, Rudas M, Mader R, Dubsky P, Rottenfusser A, Gnant M,
Zielinski C, Steger G
Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic
breast cancer
Cancer Chemother Pharmacol 2008; 62: 903-10
IF: 2,568
2
Univ. Prof. Dr. Michael Gnant
198
Originalarbeiten
- 23 -
Stadler G, Wieser M, Streubel B, Stift A, Friedl J, Gnant M, Niederle B, Katinger H, Pfragner R, Grillari J, Voglauer R
Low telomerase activity: possible role in the progression of human medullary thyroid carcinoma
Eur J Cancer 2008; 44: 866-75
199
IF: 4,454
Rudas M, Lehnert M, Huynh A, Jakesz R, Singer C, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Grill
R, Stierer M, Gnant M, Filipits M, for the ABCSG
Cyclin D1 expression in breast cancer and tamoxifen therapy
Clin Cancer Res 2008; 14: 1767-74
200
IF: 6,250
Li J, Haensch W, Rudas M, Kemmer W, Warnick P, Fischer J, Gnant M, Schlag PM, Bembenek A
The localization of small tumor deposits in the SLN predicts Non-SLN macrometastases in breast
cancer patients
Eur J Surg Oncol 2008; 34: 857-862
201
IF: 3,917
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
Adjuvant chemotherapy in oestrogen-receptor-poor early breast cancer: patient-level meta-analysis
of randomised trials
Lancet 2008; 371: 29-40
IF: 28,638
202
Mlineritsch B, Tausch C, Singer C, Luschin-Ebengreuth G, Jakesz R, Ploner F, Stierer M, Melbinger E, Menzel C, Urbania
A, Fridrik M, Steger G, Wohlmuth P, Gnant M, Greil R, on behalf of the ABCSG
Exemestane as primary systemic treatment for hormone receptor positive postmenopausal breast
cancer patients: a phase II trial opf the Austrian Breast and Colorectal Cancer Study Group (ABCSG
-17)
Breast Cancer Res Treat 2008; 112: 203-213
IF: 4,453
203
Dubsky P, Sevelda P, Jakesz R, Hausmaninger H, Samonigg H, Seifert M, Desnison U, Mlineritsch B, Steger G, Kwansy
W, Stoeger H, Bartsch R, Stierer M, Taucher S, Fridrik M, Schippinger W, Greil R, Poetter R, Gnant M
Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary
breast cancer patients receiving adjuvant CMF chemotherapy
Clin Cancer Res 2008; 14: 2082-7.
204
IF: 6,250
Sahora K, Trenkwitz D, Akan B, Kuehrer I, Goetzinger P, Gnant M
Moderne Tumortherapie des Pankreaskarzinoms
J Gastroenterol Hepatol Erkr 2008; 6: 17-24
205
IF: 0,000
Pestalozzi BC, Francis P, Quinaux E, Dolci S, Azambuja E, Gelber RD, Viale G, Balil A, Andersson M, Nordenskjöld B,
Gnant M, Gutierrez J, Lang I, Crown JPA, Piccart-Gebhart M, on behalf of the BIG 02-98 Collaborative Group
Is risk of central nervous system (CNS)-relaps related to adjuvant taxane treatment in node-positive
breast cancer? Results of the CNS-substudy in the Intergroup phase III BIG 02-98 trial
Ann Oncol 2008; 19: 1837-41
206
IF: 5,179
Sahora K, Akan B, Kuehrer I, Goetzinger P, Gnant M
Neoadjuvante Therapie des Pankreaskarzinoms
Wien Klin Wochenschr 2008; 3: 6-9
IF: 0,885
2
Univ. Prof. Dr. Michael Gnant
207
Originalarbeiten
- 24 -
Dubsky P, Gnant M
(Neo-)Adjuvant Chemotherapy in Breast Cancer - Trials, errors and new Rationales from the SABCS
2007
memo 2008; 1: 23-36
208
IF: 0,000
Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kaessmann H, Piswanger-Soelkner C, Seifert M,
Schippinger W, Menzel C, Dubsky P, Fitzal F, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Jakesz R, on behalf of
the
ABCSGendocrine therapy plus zoledronic acid in premenopausal women with early-stage breast
Adjuvant
cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy
Lancet Oncology 2008; 9:840-9.
209
IF: 12,274
Fitzal F, Mittlboeck M, Trischler H, Krois W, Nehrer G, Deutinger M, Jakesz R, Gnant M
Breast-conserving therapy for centrally located breast cancer
Ann Surg 2008; 247: 470-6
210
IF: 7,446
Gnant M, Dubsky P, Fitzal F, Steger G, Jakesz R
Adjuvant endocrine Therapy in premenopausal women with breast cancer
Breast Care 2008; 3: 311-6
211
IF: 0,242
Ludwig H, Auberger T, Burghuber O, Gnant M, Hopfinger G, Jaeger U, Keil F, Kornek G, Linkesch W, Petrau E, Pirker R,
Pittermann E, Reinthaller A, Samonigg H, Steger G, Stockenhuber F, Studnicky M, Weiss G, Zielinski C
Einsatz von Erythropoease-stimulierenden Proteinen bei anämischen Patienten mit malignen
Erkrankungen
Wien Klin Wochenschr 2008; 120: 507-13
212
IF: 1,000
Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Poestlberger S, Menzel C, Jakesz R, Kubista E, Marth C,
Greil R, on Behalf of the ABCSG
Adjuvant endocrine therapy plus zoledronic acid in premenopausal breast cancer
New Engl J Med 2009; 360:679-91
213
IF: 52,589
Riedl O, Fitzal F, Mader N, Dubsky P, Rudas M, Mittlboeck M, Gnant M, Jakesz R
Intraoperative frozen section analysis for breast conservingt therapy in 1.016 patients with breast
cancer
Eur J Surg Oncol 2009; 35: 264-70
214
IF: 3,917
Gnant M
To measure the unmeasurable
World J Surgery 2009; 33: 52-3
215
IF: 2,696
Singer C, Hudelist G, Fuchs E, Koestler W, Fink-Retter A, Gschwantler-Kaulich D, Gnant M, Rudas M, Czerwenka K,
Kubista E
Incomplete surgical resection of DCIS results in activation of HER-2 in residual breast cancer cells
Endocrine Rel Cancer 2009; 16: 73-83
IF: 5,193
2
Univ. Prof. Dr. Michael Gnant
216
Originalarbeiten
- 25 -
Gnant M
The evolving role of Zoledronic Acid in early breast cancer
OncoTargets and Therapy 2009; 2: 95-104
217
IF:
Bachleitner-Hofmann T, Friedl J, Hassler M, Hayden H, Dubsky P, Sachet M, Rieder E, Pfragner R,
Brostjan C, Riss S, Niederle B, Gnant M, Stift A
Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in
patients with metastatic medullary thyroid carcinoma
Oncol Rep. 2009; 21:1585-92
218
IF: 1,588
Sahora K, Kührer I, Trenkwitz D, Friedl J, Sautner T, Goetzinger P, Gnant M
Pankreaskarzinom und periampulläres Karzinom
J Gastroenterol Hepatol Erkr 2009; 7: 36-46
219
IF: 0,669
Hayden H, Fridl J, Dettke M, Sachet M, Hassler M, Dubsky P, Bachleitner-Hofmann T, Gnant M, Stift A
Cryopreservation of monocytes is superior to cryopreservation of immature or semi-mature dendritic
cells for dendritic cell based immunotherapy
J Immunoth 2009; 32: 658-64
220
IF: 3,203
Blaha P, Dubsky P, Fitzal F, Bachleitner-Hofmann T, Steger G, Jakesz R, Gnant M
Breast cancer chemoprevention - a vision not yet realised
Eur J Cancer Care 2009; 18; 438-46
221
IF: 1,038
Gnant M, Dubsky P, Fitzal F, Bachleitner-Hofmann T, Exner R, Blaha P, Jakesz R, Schippinger W, Greil R
Bisphosphonates as adjuvant treatment for breast cancer
Curr Breast Canc Rep 2009; 1: 54-63
222
IF:
Bartsch R, Mlineritsch B, Gnant M, Niernberger T, Pluschnig U, Greil R, Wenzel C, Sevelda P, Thaler J, Rudas M, Pober
M, Zielinski CC, Steger GG; on behalf of the Austrian Fulvestrant Registry.
The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in
postmenopausal patients with metastatic breast cancer
Breast Cancer Res Treat 2009; 115: 373-80
223
IF: 4,453
Blaha P, Exner R, Dal Borgo A, Bigenzahn S, Panhofer P, Riedl O, Schoppmann S, Bachleitner-Hofmann T, Sporn E,
Pluschnig U, Fitzal F, Steger G, Jakesz R, Dubsky P, Gnant M
Is endocrine Therapy really pleasant? Considerations about the long-term use of antihormonal
therapy and its benefit/side effect ratio
Breast Care 2009; 4:155-61
224
IF: 0,500
Coleman R, Gnant M
New results from the use of bisphosphonates in cancer patients.
Curr Opin Support Palliat Care 2009; 3: 213-8
IF: 2,073
2
Univ. Prof. Dr. Michael Gnant
225
Originalarbeiten
- 26 -
Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ; Panel members.
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary
therapy of early breast cancer 2009.
Ann Oncol 2009; 20:1319-29
226
IF: 5,647
Beslija S, Bonneterre J, Burstein HJ, Cocquyt V, Gnant M, Heinemann V, Jassem J, Köstler WJ, Krainer M,
Menard S, Petit T, Petruzelka L, Possinger K, Schmid P, Stadtmauer E, Stockler M, Van Belle S, Vogel C,
Wilcken N, Wiltschke C, Zielinski CC, Zwierzina H; for the Central European Cooperative Oncology Group
Third Consensus on Medical Treatment of Metastatic Breast Cancer
Ann Oncol 2009; 20: 1771-85
227
IF: 5,647
Gnant M, Dubsky P, Fitzal F, Blaha P, Schoppmann SF, Steger G, Marth C, Samonigg H, Huettner K, Fohler H,
Ruecklinger E, Jakesz R, Greil R, on behalf of the Austrian Breast and Colorectal Cancer Study Group (ABCSG)
Maintaining Bone Density in patients undergoing treatment for breast cancer: is there an adjuvant
benefit?
Clin Breast Cancer 2009; 9: s18-27
228
IF: 2,065
Filipits M, Rudas M, Heinzl H, Jakesz R, Kubista E, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W,
Nader A, Stierer M, Gnant M
Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive
breast cancer patients receiving adjuvant tamoxifen therapy
Clin Cancer Res 2009; 15: 5888-94
229
IF: 6,747
Gnant M
Bisphosphonates in the prevention of disease recurrence: Current results and ongoing trials
Curr Cancer Drug Targets 2009; 9: 824-33
230
IF: 5,385
Akan B, Sahora K, Puhalla H, Gnant M, Jakesz R, Goetzinger P
Cystic neoplasms of the pancreas: Conservative or operative treatment?
Eur Surg 2009; 40:220-6
231
IF: 0,629
Gnant M, Blaha P, Dubsky P, Exner R, Fitzal F, Sporn E, Panhofer P, DalBorgo A, Bigenzahn S, Jakesz R, Steger G
Adjuvant bisphosphonates in endocrine-responsive breast cancer: what is their place in therapy?
Ther Adv Med Oncol 2009; 1: 123-36
232
IF:
Gnant M
Adjuvant endocrine therapy in premenopausal women with breast cancer
BCO 2009; 12 (5): 1-8 (e8)
233
IF: 0,000
Bartsch R, DeVries C, Pluschnig U, Dubsky P, Horvath Z, Gampenrieder S, Rudas M, Mader R, Rottenfusser A, Wiltschke
C, Gnant M, Zielinski CC, Steger GG
Predicting for activity of second-line trastuzumab-based therapy in HER2-positive advanced breast
cancer
Br J Cancer 2009; 9: 367
IF: 4,346
2
Univ. Prof. Dr. Michael Gnant
234
Originalarbeiten
- 27 -
Gnant M, Steger GG
Fighting overtreatment in adjuvant breast cancer therapy
Lancet 2009; 374: 2029-30
235
IF: 30,758
Gnant M
Bisphosphonates in the adjuvant treatment of early breast cancer
Breast Cancer Res 2009; 11: S17
236
IF: 4,696
Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleaoni M, Coombes C,
Snowdon C, Gnant M, Jakesz R, Kaufmann M, Boccardo F, Godwin J, Davies C, Peto R, for the Aromatase Inhibitor
Overview
Group of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen
Meta-analysis
J Clin Oncol 2010; 28: 509-18
237
IF: 18,970
Kaufmann M, von Mickwitz G, Morrow M, The Biedenkopf Expert Panel Members
Local-Regional Treatment of Primary Breast Cancer: Consensus Recommendation from an
International Expert Panel
Cancer 2010; 116: 1184-9
238
IF: 5,131
Gnant M, Eidtmann H
The anti-tumor effect of bisphosphonates: ABCSG-12, ZO-FAST and more...
Crit Rev Onc Hem 2010; 74: S2-6
239
IF: 4,589
Lux MP, Nowitzki C, Wallwiener D, Kreienberg R, Jonat W, Gnant M, Beckmann M
Mammakarzinom: Bisphosphonate in der Adjuvanz - auch aus gesundheitsökonomischer Sicht eine
sinnvolle Therapie
Geburtsh Frauenheilk 2010; 70: 8-11
240
IF: 0,342
Delea T, Taneja C, Sofrygin O, Kaura S, Gnant M
Cost-Effectiveness of Zoledronic Acid Plus Endocrine Therapy in Premenopausal Women with
Hormone-Responsive Early Breast Cancer
Clin Breast Cancer 2010; 4: 267-74
241
IF: 2,790
Gnant M
The evolution of bone-targeted therapies: Introduction
Sem Oncol 2010; 37: S1
242
IF: 3,355
Lux MP, Reichelt C, Wallwiener D, Kreienberg R, Jonat W, Gnant M, Beckmann M
Results of the Zometa® Cost-utility model for the German healthcare system based omn the results
of the ABCSG-12 study
Onkologie 2010; 33: 360-8
IF: 1,153
2
Univ. Prof. Dr. Michael Gnant
243
Originalarbeiten
- 28 -
Gnant M
Neue Studiendaten zur endokrinen Langzeittherapie
Gyn Spectrum 2010; 1: 4-6
244
IF: 0,000
Starlinger P, Moll H, Assinger A, Nemeth C, Gruenberger B, Gruenberger T, Kuehrer I, Schoppmann S, Gnant M, Brostjan
C
Thrombospondin-1: a unique marker to identify in vitro platelet activation when monitoring in vitro
processes
J Thromb Hemosta 2010; 8: 1809-19
245
IF: 4,701
Gnant M
Can oral bisphophonates really reduce the risk of breast cancer in healthy women?
J Clin Oncol 2010; 28: 3548-51
246
IF: 18,970
Gampenrieder S, Bartsch R, Scheuer R, Pluschnig U, Dubsky P, Gnant M, Zielinski C, Steger G
Capecitabine and vinorelbine as an all-oral chemotherapy in HER2-negative locally advanced and
metastatic breast cancer
Breast Care 2010; 5: 158-162
247
IF: 0,364
Gnant M
Neoadjuvant Treatment and Breast Conserving Surgery - a success of clinical research in breast
cancer
Wien Med Wochenschr 2010; 160: 163-6
248
IF: 0,000
Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Correa C, McGale P, Taylor C, Wang Y, Clarke M, Davies C,
Peto R, Bijker N, Solin L, Darby S
Overview of the ransomized trials of radiotherapy in ductal carcinoma in situ of the breast
J Natl Cancer Inst Monogr 2010; 41: 162-77
249
IF: 14,697
Gnant M, Dubsky PC
Closing in on the unknown enemy
Lancet Oncol 2010; 11:402-3
250
IF: 17,764
Bartsch R, Steger G, Gnant M, Ziebermayr R
Breast Cancer: Rank Ligand Inhibition
Breast Care 2010; 5: 320-325
251
IF: 0,364
Schoppmann S,Tamandl D, Roberts L, Jomrich G, Schoppmann A, Zwrtek R, Dubsky P, Gnant M, Jakesz R, Birner P
HER-2/neu-expression correlates with vascular endothelial growth factor-C and lymphangiogenesis
in llymph node positive breast cancer
Ann Oncol 2010; 21: 955-60
IF: 6,452
2
Univ. Prof. Dr. Michael Gnant
252
Originalarbeiten
- 29 -
Neville-Webbe H, Gnant M, Coleman R
Potential anticancer properties of bisphosphonates
Semin Oncol 2010; 7: S53-65
253
IF: 3,355
Mouridsen H, Lonning P, Beckmann M, Blackwell K, Doughty J, Gligorov J, Llombart-Cussac A, Robidoux A, Thürlimann B,
Gnant M
Use of aromatase inhibitors and bisphosphonates as an anti-cancer therapy in postmenopausal
breast cancer
Expert Rev Anticancer Ther 2010; 11: 1825-36
254
IF: 2,976
Gnant M, Hadji P
Prevention of bone metastases and management of bone health in early breast cancer
Breast Cancer Research 2010; 12: 216
255
IF: 4,859
Michlmayr A, Bachleitner-Hofmann T, Baumann S, Marchetti-DeschmannM , Rech-Weichselbraun I, Burghuber C,
Pluschnig U, Bartsch R, Graf A, Greil R, Allmaier G, Steger G, Gnant M, Bergmann M, Oehler R
Modulation of plasma complement by the initial dose of epirubicin / docetaxwl therapy in breast
cancer and its predictive value
Br J Cancer 2010; 103: 1201-8
256
IF: 4,831
Gnant M
10 years of ATAC: one question answered, many others unresolved
Lancet Oncology 2010; 11: 1109-10
257
IF: 17,764
Gnant M
Adjuvant Bisphosphonate therapy in postmenopausal breast cancer patients
Breast Care 2010; 5: 298-304
258
IF: 0,364
Hadji P, Gnant M, Aapro M, Lipton A, Coleman R
Dosing of Zoledronic Acid throughout the treatment continuum in breast cancer
Crit Rev Oncol Hematol 2011; 79:175-88
259
IF: 4,411
Tausch C, Steger G, Haid A, Jakesz R, Fridrik M, Reitsamer R, Poestlberger S, Lang A, Gnant M, Greil R, on behalf of the
ABCSG
Sentinel Node Biopsy after primary chemotherapy in breast cancer: A note of caution from results
from ABCSG-14
Breast J 2011; 17: 230-8
260
IF: 1,643
Gnant M
Adjuvant Zoledronic Acid reduces disease recurrence in breast cancer:
Antitumor effects on the seed and the soil
Curr Cancer Ther Rev 2011; 7: 111-18
IF:
2
Univ. Prof. Dr. Michael Gnant
261
Originalarbeiten
- 30 -
Starlinger P, Brugger P, Schauer D, Sommerfeldt S, Tamandl D, Kuehrer I, Schoppmann S, Gnant M, Brostjan C
Myelosuppression of thrombocytes and monocytes is associated with a lack of synergy between
chemotherapy and anti-VEGF treatment
Neoplasia 2011; 13; 5: 419-27
IF: 5,946
262
Kerjaschki D, Bago-Horvath Z, Rudas M, Sexl V, Wolbank S, Schneckenleithner C, Wolbank S, Bartel G, Krieger S, Kalt R,
Hantusch B, Keller T, Nagy-Bojarski K, Huttary N, Raab I, Lackner K, Krautgasser K, Schachner H, Kaserer K, Rezar S,
Madlener
S, Vonach
C, Davidovits
A, Nosaka
H, Haemmerle M,
Viola K, Dolznig
H, Schreiber
M, Nader lymph
A, Mikulits
W,
Lipoxigenase
mediates
Invasion
of intrametastatic
lymphatic
vessels
and propagates
node
metastasis of human mammary carcinoma xenografts in mouse
IF: 13,069
J Clin Invest 2011; 132: 2000-12
263
Sahora K, Kuehrer I, Fitzal F, Schindl M, Koelblinger C, Goetzinger P, Gnant M
NeoGemTax - Gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetatasized pancreatic cancer
World J Surg 2011; 35: 1580-9
264
IF: 2,362
Gnant M
Intravenous bisphosphonates for breast cancer: Impact on patient outcomes and scientific concepts
Breast Disease 2011; 33: 71-81
265
IF:
Starlinger P, Alidzanovic L, Schauer D, Brugger P, Sommerfeldt S, Kuehrer I, Schoppmann S, Gnant M, Brostjan C
Platelet-stored angiogenesis factors: Clinical monitoring is prone to artifacts
Disease Markers 2011; 31: 55-65
266
IF: 1,642
Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengruth G, Heck D, Menzel C, Jakesz R, Seifert M, Hubalek M, Pristauz G,
Bauernhofer T, Eidtmann H, Eiermann W., Steger G, Kwasny W, Dubsky P, Hochreiner G,, Forsthuber EP, Fesl C, Greil R,
on
behalf ofendocrine
the ABCSG therapy plus zoledronic acid in premenopausal women with early breast cancer:
Adjuvant
62-month follow-up from ABCSG-12
Lancet Oncol 2011; 12: 631-41
267
IF: 22,589
Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer C, Dietze O, Greil R, Jelen A, Sevelda P, Freibauer C, Müller V,
Jänicke F, Schmidt M, Kölbl H, Rody A, kaufmann M, Schroth W, Brauch H, Schwab M, Fritz P, Weber KE, Feder IS,
Henning
G, Gehrmann
M, GnantofM distant recurrence in estrogen recpetor-positive HER2-negative breast
A new molecular
predictor
cancer adds independent information to conventional clinical risk factors
Clin Cancer Res 2011; 17: 6012-20
268
IF: 7,742
Gnant M
Zoledronic Acid in Breast Cancer: Latest Findings and Interpretations
Ther Adv Med Oncol 2011; 3: 293-301
269
IF:
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thuerlimann B, Senn HJ, & Panel members
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen
International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
Ann Oncol 2011; 22: 1736-47
IF: 6,425
2
Univ. Prof. Dr. Michael Gnant
270
Originalarbeiten
- 31 -
Gnant M, Harbeck N, Thomssen C
St. Gallen 2011: Summary of the consensus discussion
Breast Care 2011; 6: 136-41
271
IF: 0,446
Fitzal F, Riedl O, Mittlboeck M, Dubsky P, Bartsch R, Steger G, Jakesz R, Gnant M
Oncologic safety of breast conserving surgery after tumor downsizing by neoadjuvant therapy: A
retrospective single centre cohort study
Breast Cancer Res Treatm 2011; 127: 121-128
272
IF: 4,431
Öfner D, DeVries A, Schaberl-Mosef R, Greil R, Rabl H, Tschmelitsch J, Zitt M, Kapp K, Fastner G, Keil F, Eisterer W,
Jäger R, Offner F, Gnant M, Thaler J, for the TAKO 05/!BCSG R02 Trial Investigators
Preoperative oxaliplatin, capecitabine and external beam readiotherapy in patients with newly
diagnosed, primary operable, cT3NxM0 low rectal cancer - a Phase II study
Strahlenther Oncol 2011; 187: 100-7
273
IF: 3,561
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Relevance of breast hormone receptors and other factors to the efficacy of adjuvant tamoxifen:
patient-level meta-analysis of randomised trials
Lancet 2011; 378: 771-84
274
IF: 38,278
Gnant M, Piccart-Gebhart M, Goldhirsch A, Baselga J, Cameron D, Di Leo A, Dowsett M, Gelber M, von Mickwitz G,
Wadvogel C, Straehle C
Developing an international network for breast cancer research: the Breast International Group (BIG)
experience
Clin Invest 2011; 1(5): 623-28
275
IF: 13,069
Starlinger P, Brugger P, Reiter C, Schauer D, Sommerfeldt S, Tamandl D, Kuehrer I, Schoppmann S, Gnant M, Brostjan C
Discrimination between circulating endothelial cells and blood cell populations with overlapping
phenotype reveals distinct regulation and predictive potential in cancer therapy
Neoplasia 2011; 13: 980-90
276
IF: 5,946
Pfeiler G, Koenigsberg R, Fesl C, Mlineritsch B, Stoeger H, Singer C, Poestlberger S, Steger G, Seifert M, Dubsky P,
Taucher S, Samonigg H, Bjelic-Radisic V, Greil R, Marth C, Gnant M
Impact of Body Mass Index on the efficacy of endocrine therapy in premenopausal patients with
breast cancer: An analysis of the prospective ABCSG-12 trial
J Clin Oncol 2011; 29: 2653-9
277
IF: 18,372
Hadji P, Aapro M, Body J, Bundred N, Brufsky A, Coleman R, Gnant M, Guise T, Lipton A
Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast
cancer: Practical guidance for prevention and treatment
Annals of Oncology 2011; 22: 2546-55
278
IF: 6,425
Gnant M
Targeted therapies: Adjuvant bisphosphonates - an option with low estrogen?
Nature Reviews Clinical Oncology 2011; 8: 698-9
IF: 11,963
2
Univ. Prof. Dr. Michael Gnant
279
Originalarbeiten
Pagani O, Partridge A, Korde L, Badve S, Bartlett J, Albain K, Gelber R, Goldhirsch A; Breast International Group; North
American Breast Cancer Group Endocrine Working Group
Pregnancy after breast cancer: if you wish, ma'am
Breast Cancer Res Treatm 2011; 129: 309-17
280
IF: 4,431
Sahora K, Kuehrer I, Eisenhut A, Akan B, Koellblinger C, Goetzinger P, Teleky B, Jakesz R, Pecl-Radosavlejvid M,
Ba'ssalamah A, Zielinski C, Gnant M
NeoGemOx - Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer
Surgery 2011; 143: 311-20
281
- 32 -
IF: 3,103
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast
cancer mortality in women with early breast cancer: analysis of individual patient data on 10,801
women2011;
in 17378:
randomised
Lancet
1707-16 trials
IF: 38,278
282
Bago-Horvath Z, Rudas M, Dubsky P, Singer C, Dietze O, Greil R, Jelen A, Boehm G, Jasarevic Z, Lang A, Gruber C,
Poestlberger S, Filipits M, Gnant M, on behalf of the ABCSG
Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal
women with low proliferating breast cancer
Clin Cancer Res 2011;17: 7828-34
283
IF: 7,742
Gnant M
Bisphosphonates in the adjuvant treatment of breast cancer - Rationale and clinical data
Clin Invest 2011; 1: 97-107
284
IF: 13,069
Bartsch R, Berghoff A, Pluschnig U, Bago-Horvath Z, Dubsky P, Rottenfusser A, DeVries C, Rudas M, Fitzal F, Dieckmann
K, Mader R, Gnant M, Zielinski C, Steger G
Impact of anti-HER2 therapy on overall survival in HER2-positive metastatic breast cancer patients
with brain metastases
Br J Cancer 2012; 106: 25-31
285
IF: 5,082
Gnant M, Steger GG
Dual HER2 inhibition in breast cancer treatment
Lancet 2012; 379; 596-8
286
IF: 39,060
Knauer M, Gnant M, Fitzal F, Panel Members
Results of the first Austrian multidisciplinary expert panel on controversies in local treatment of breast
cancer
Breast Care 2012; 7: 61-66
287
IF: 0,680
Tausch C, Taucher S, Dubsky P, Seifert M, Reitsamer R, Kwasny W, Jakesz R, Fitzal F, Filipcic L, Fridrik M, Greil R, Gnant
M
Prognostic Value of Number of Removed Lymph Nodes, Number of Involved Lymph Nodes, and
Lymph Node Ratio in 7502 Breast Cancer Patients Enrolled onto Trials of the Austrian Breast and
Colorectal
Cancer
Study
Group (ABCSG)
Ann
Surg Oncol
2012;
19: 1808-17
IF: 4,166
2
Univ. Prof. Dr. Michael Gnant
288
Originalarbeiten
- 33 -
Gnant M
Zoledronic Acid in the treatment of early stage breast cancer: Is there a final verdict?
Curr Oncol Reports 2012; 14:35–43
289
IF: 3,327
Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, Denkert C, Eiermann W, Gnant M,
Harris JR, Karn T, Liedtke C, Mauri D, Rouzier R, Ruckhaeberle E, Semiglazov V, Symmans WF, Tutt A, Pusztai L
Recommendations from an International Consensus Conference on the Current Status and Future of
Neoadjuvant Systemic Therapy in Primary Breast Cancer
Ann Surg Oncol 2012; 19: 1508-16
290
IF: 4,166
Hadji P, Aapro M, Costa L, Gnant M
Antiresorptive treatment options and bone health in cancer patients - safety profile and clinical
considerations
Cancer Treatm Rev 2012; 38, 815-24
291
IF: 6,054
Baselga J, Campone M, Piccart M, Burris HA, Rugo, HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck
JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu C, Mukhopadhyay P, Lebwohl D, Hortobagyi GN
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer
N Eng J Med 2012; 366: 520-9
292
IF: 53,298
Exner R, Krois W, Mittlböck M, Dubsky P, Jakesz R, Gnant M, Fitzal F
Objetively measured breast symmetry has no influence on quality of life in breast cancer patients
Eur J Surg Oncol 2012; 38: 130-6
293
IF: 2,614
Resch G, DeVries A, Oefner D, Eisterer W, Rabl H, Jagoditsch M, Gnant M, Thaler J, on behalb of the ABCSG
Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locally
advanced rectal cancer - A two stage phase II clinical trial
Radiother Oncol 2012; 102: 10-3
294
IF: 5,580
Hadji P, Gnant M, Body JJ, Bundred NJ, Brufsky A, Coleman RE, Guise T, Lipton A, Aapro MS
Cancer treatment-induced bone loss in premenopausal women: A need for therapeutic intervention?
Cancer Treatm Rev 2012; 38: 798-806
295
IF: 6,054
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses
of long-term outcome among 100 000 women in 123 randomised trials
Lancet 2012; 379: 432-44
296
IF: 39,060
Gnant M, Dubsky P, Hadji P
Bisphosphonates: prevention of bone metastases in breast cancer
Recent Results Cancer Res. 2012;192:65-91
IF: 2,000
2
Univ. Prof. Dr. Michael Gnant
297
Originalarbeiten
Barrios C, Forbes JF, Jonat W, Conte P, Gradishar W, Guzudar A, Gelmon K, Gnant M, Bonneterre J, Toi M, Hudis C,
Robertson J
The sequential use of endocrine treatment for advanced breast cancer: where are we?
Ann Oncol 2012; 23: 1378-86
298
- 34 -
IF: 7,384
Fitzal F, Mittlboeck M, Steger G, Bartsch G, Rudas M, Dubsky P, Riedl O, Jakesz R, Gnant M
Neoadjuvant chemotherapy increases the rate of breast conservation on lobular-type breast cancer
patients
Ann Surg Oncol 2012; 19: 519-26
IF: 4,166
299
Dubsky P, Jakesz R, Mlineritsch B, Poestlberger, Graz2, Kwasny W, Tausch C, Samonigg H, Haider K, Fitzal F, Singer C,
Stierer M, Sevelda P, Luschin-Ebengreuth G, Taucher S, Rudas M, Bartsch R, Steger G, Greil R, Filipcic L, Gnant M, on
behalf
of the and
ABCSG
Taxoxifen
Anastrozole as a sequencing strategy: A randomized controlled trial in
postmenopausal patients with endocrine-responsive early breast cancer: Final results from the
Breast
Cancer Study Group
JAustrian
Clin Oncol
2012;and
30: Colorectal
722-8
IF: 18,372
300
Gnant M
Anticancer activity of bisphosphonates in breast cancer
Anticancer Agents Med Chem 2012; 12: 114-22
301
IF: 3,144
Berghoff A, Bago-Horvath Z, De Vries C, Dubsky P, Pluschnig U, Rudas M, Rottenfusser A, Knauer M, Eiter H, Fitzal F,
Dieckmann K, Mader RM, Gnant M, Zielinski CC, Steger GG, Preusser M, Bartsch R.
Brain metastases free survival differs between breast cancer subtypes
Br J Cancer 2012; 106: 440-6
302
IF: 5,082
Schoppmann SF, Berghoff A, Dinhof C, Jakesz R, Gnant M, Fitzal F, Dubsky P, Jesch B, Birner P
Podoplanin-expressing cancer-associated fibroblasts are associated with poor prognosis in invasive
breast cancer
Breast Cancer Res Treatm 2012; 134: 237-44
303
IF: 4,469
Gnant M, Balic M, Petru E, Raunik W, Singer CF, Steger GG, Watzke IM, Brodowicz T
Treatment of bone metastases in patients with advanced breast cancer
Breast Care 2012; 7: 92-8
304
IF: 0,680
Coleman RE, Gnant M, Morgan G, Clezardin P
Bone Targeted Agents: Effects on disease progression and mortality in solid tumour and
haematological cancers
J Nat Cancer Inst 2012; 104: 1059-1067
305
IF: 14,700
Gnant M
Overcoming endocrine resistance in breast cancer: importance of mammalian target of rapamycin
(mTOR) inhibition
Expert Rev of Anticancer Ther 2012; 12: 1579-89
IF: 2,652
2
Univ. Prof. Dr. Michael Gnant
306
Originalarbeiten
Bartsch R, Bago-Horvath Z, Berghoff A, DeVries C, Pluschnig U, Dubsky P, Rudas M, Mader RM, Rottenfusser A, Fitzal F,
Gnant M, Zielinski CC, Steger GG
Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with
metastatic breast cancer
Eur J Cancer 2012; 48: 1932-8
307
- 35 -
IF: 5,061
Hadji P, Coleman R, Gnant M, Green J
The impact of menopause on bone and implications for breast cancer growth and metastasis
Ann Oncol 2012; 23: 2782-90
308
IF: 7,384
Gnant M, Clezardin P
Direct and indirect Anticancer Activity of Bisphosphonates: A review of published literature
Cancer Treatm Rev 2012; 38: 407-15
309
IF: 6,054
Hubalek M, Gnant M, Bartsch R, Kapp K, Lang A, Lax S, Lukas P, Neunteufel W, Reitsamer R, Sandbichler P, Schrenk P,
Tamussino K, Pristauz G, Tschmelitsch J, Singer C, Zeimet A, Marth C
Axilladissektion bei positivem Sentinel-Lymphknoten - Ergebnisse Innsbrucker Konsuskonferenz
Geburtsh Frauenheilk 2012; 72:299–304
310
IF: 0,848
Gnant M, Beermann B
8th European Breast Cancer Conference (EBCC-8)
Breast Care 2012; 7: 170-6
311
IF: 0,680
Gnant M
Adjuvant bisphosphonates: a new standard of care?
Curr Opin Oncol 2012, 24:635-42
312
IF: 4,101
Thomssen C, Gnant M, Harbeck N
Entwicklungen der forschenden Pharmaindustrie
Breast Care 2012; 7: 155-64
313
IF: 0,680
Arnold T, Micklmayr A, Baumann S, Burghuber C, Pluschnig U, Bartsch R, Steger G, Gnant M, Bergmann M, BachleitnerHofmann T, Oehler R
Plasma HMGB-1 after the initial dose of epirubicin/docetaxel in cancer.
Eur J Clin Invest 2013; 43:286-91
314
IF: 3,365
Gnant M
The Role of Mammalian Target of Rapamycin (mTOR) Inhibition in the Treatment of Advanced
Breast Cancer
Curr Oncol Rep 2013; 15: 14-23
IF: 2,545
2
Univ. Prof. Dr. Michael Gnant
315
Originalarbeiten
Dubsky P, Filipits M, Jakesz R, Rudas M, Singer C, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D,
Schmidt M, Gehrmann M, Petry C, Weber KE, Kronenwett R, Brase JC, Gnant M
EndoPredict improves the prognostic classification derived from common clinical guidelines in ERpositive, HER2-negative early breast cancer
Ann Oncol 2013; 24:640-7
316
- 36 -
IF: 7,384
Campone M, Lebrun F, Beck JT, Gnant M, Neven P, Pritchard KI, Bachelot T, Provencher L, Rugo HS, Piccart M,
Hortobagyi GN, Nunzi M, Heng D, Baselga J, Komorowski A, Noguchi S, Horiguchi J, Bennett L, Ziemiecki R, Zhang J,
Cahana
A, Taran T,
Sahmoud
T, Burris
HA
Health-related
quality
of life
and disease
symptoms in postmenopausal women with advanced breast
cancer treated with everolimus plus exemestane versus exemestane monotherapy
Curr Med Res Opinion 2013; 24: 2206-23
IF: 2,380
317
Gnant M, Pfeiler G, Stoeger H, Mlineritsch B, Fitzal F, Balic M, Kwasny W, Seifert M, Stierer M, Dubsky P, Greil R, Steger
G, Samonigg H, Fesl C, Jakesz R, on behalf of the ABCSG
The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment
with anastrozole in postmenopausal patients with breast cancer - an analysis of the randomized
ABCSG
6a trial
Brit
J Cancer
2013; 109: 589-96
IF: 5,061
318
Dubsky P, Brase JC, Jakesz R, Rudas M, Singer CF, Greil T, Dietze O, Luisser I, Klug E, Sedivy R, Bachner R, Mayr D,
Schmidt M, Gehrmann MC, Petry C, Weber KE, Fisch K, Kronenwett R, Gnant M, Filipits M, on behalf of the ABCSG
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2breast cancer patients
Br J Cancer 2013; 109: 2959-64
319
IF: 5,082
Thaler J, Ay C, Mackman N, Metz-Schimmerl S, Stift J, Kaider A, Müllauer L, Gnant M, Scheithauer W, Pabinger I
Microparticle-associated tissue factor activity in patients with pancreatic cancer: Correlation with
clinicopathological features
Eur J Clin Invest 2013; 43: 277-85
320
IF: 3,365
Harbeck N, Thomssen C, Gnant M
St. Gallen 2013: Brief preliminary summary of the Consensus discussion
Breast Care 2013; 8: 102-9
IF: 0,911
321
Burris HA, Lebrun F, Hugo HS, Beck JT, Piccart M, Neven P, Baselga J, Petrakova K, Hortobagyi G, Komorowski A,
Chouinard E, Young R, Gnant M, Pritchard KI, Bennett L, Rixxi JF, Bauly H, Taran T, Sahmoud T, Noguchi S
Health-related Quality of Life of Advanced Breeast Cancer Patierns treated with Everolimus plus
Exemestane versus Placebo plus Exemestane in the Phase 3, randomized, controlled, BOLERO-2
trial
Cancer 2013; 119: 1908-15
IF: 3,662
322
Gnant M, Greil R, Hubalek M, Steger G
Everolimus in postmenopausal, hormone receptor-positive advanced breast cancer - Summary and
results of an Austrian Expert Panel discussion
Breast Care 2013; 8: 293-9
323
IF: 0,911
Pfeiler G, Stoeger H, Dubsky P, Mlineritsch B, Singer C, Balic M, Fitzal F, Moik M, Kwasny W, Selim U,
Renner K, Ploner F, Steger GG, Seifert M, Hofbauer F, Sandbichler P, Samonigg H, Jakesz R, Greil
R,
Fesl C,
M, on
behalf of the ABCSG
Efficacy
of Gnant
tamoxifen
± aminoglutethimide
in normal weight and overweight postmenopausal patients
with hormone-receptor positive breast cancer – an analysis of 1509 patients of the ABCSG-06 trial
Br J Cancer 2013; 108: 1408-14
IF: 5,082
2
Univ. Prof. Dr. Michael Gnant
324
Originalarbeiten
Goetz M, Suman V, Ames M, Gnant M, Filipits M, Hoskin T, Safgren S, Kuffel M, Jakesz R, Rudas M, Greil R, Dietze O,
Lang A, Offner F, Reynolds C, Weinshilboum R, Ingle J
CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Study Group trial
(ABCSG) 8
Clin Cancer Res 2013; 19: 500-7
325
IF: 7,837
Campone M, Bachelot T, Gnant M, Deleu I, Rugo HS, Pistilli B, Noguchi S, Shtivelband M, Pritchard KI, Provencher L,
Burris HA, Hart LL, Melichar B, Hoartobagyi GN, Arena F, Baselga J, Panneerselvam A, Héniquez A, El-Hashimi M, Taran
T,
Sahmoud
T, Piccart
M
Effect
of visceral
metastases
on the efficacy and safety of Everolimus in postmenopausal woem with
advanced breast cancer: subgroup analysis from the BOLERO-2 study
Eur J Cancer 2013; 49: 2621-32
326
IF: 5,061
Yardley DA, Noguchi S, Prichard KI, Burris HA, Baselga J, Gnant M, Hortobagyi GN, Capone M, Pistilli B, Piccart M,
Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Fend W, Cahana A, Taran T, Sahmoud T, Lebwohl D, Rugo HS
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final
progression-free survival analysis.
Adv Ther 2013; 30:870-84
327
IF: 2,125
Zagouri F, Sergentanis TN, Koutoulidis V, Sparber C, Steger GG, Dubsky P, Zografos GC, Psaltopoulou T, Gnant M,
Dimopoulos MA, Bartsch R
Aromatase inhibitors with or without a gonadotropin-releasing hormone analogue in male breast
cancer patients: a case series
Br J Cancer 2013; 108: 2259-63
328
- 37 -
IF: 5,082
Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ, and Panel Members
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen
International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
Ann Oncol 2013; 24: 2206-23
329
IF: 7,384
Hadji P, Coleman R, Gnant M
Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus
Crit Rev Oncol Hematol 2013; 101-11
330
IF: 5,270
Valachis A, Polyzos NP, Coleman RE, Gnant M, Eidtmann H, Brufsky AM, Aft R, Tevaarwerk AJ, Swenson K, Lind P, Mauri
D
Adjuvant Therapy With Zoledronic Acid in Patients With Breast Cancer: A Systematic Review and
Meta-Analysis
Oncologist 2013; 18 (4): 353-61
331
IF: 4,095
Berghoff AS, Bago-Horvath Z, Dubsky P, Rudas M, Pluschnig U, Wiltschke C, Gnant M, Steger GG, Zielinski CC, Bartsch
R
Impact of Her-2-Targeted Therapy on Overall Survival in Patients With Her-2 Positive Metastatic
Breast Cancer
Breast J 2013; 19:149-55
332
IF: 1,831
Gnant M
Guidelines: Usefulness and Limitations
Breast Care 2013; 8: 172-173
IF: 0,911
2
Univ. Prof. Dr. Michael Gnant
333
Originalarbeiten
Gnant M, Baselga J, Rugo HS, Noguchi S, Burris HA, Piccart M, Hortobagyi GN, Eakle J, Mukai H, Iwata H, Geberth M,
Hart LL, Hadji P, El-Hashimy M, Rao S, Taran T, Sahmoud T, Lebwohl D, Campone M, Pritchard KI
Everolimus reduced bone marker levels and progressive disease in bone in BOLERO-2
J Nat Cancer Inst 2013; 105: 654-63
334
IF: 14,336
Pritchard KI, Burris HA, Ito Y, Rugo HS, Dakhil S, Hortobagyi GN, Campone M, Csőszi T, Baselga J, Puttawibul P, Piccart
M, Heng D, Noguchi S, Srimuninnimit V, Bourgeois H, Gonzalez Martin A, Osborne K, Panneerselvam A, Taran T,
Sahmoud
T, Gnant
M of Everolimus With Exemestane Versus Exemestane Alone in Elderly Patients
Safety and
Efficacy
With HER2-Negative, Hormone-Receptor-Positive Breast Cancer in BOLERO-2
Clin Breast Cancer 2013, 13: 421-32
335
IF: 2,422
Pfeiler G, Königsberg R, Hadji P, Fitzal F, Maroske M, Dressel-Ban G, Zellinger J, Exner R, Seifert M, Singer C, Gnant M,
Dubsky P
Impact of Body Mass Index (BMI) on estradiol depletion by aromatase inhibitors in postmenopausal
women with early breast cancer
Br J Cancer 2013; 109: 1522-7
336
- 38 -
IF: 5,082
Thomssen C, Diel I, Gnant M, Goldmann-Posch U, Göschke C, Haidinger R, Janni W, Lin NU
Follow-up after breast cancer diagnosis
Breast Care 2013; 8: 457-60
337
IF: 0,911
AGO; DGS; SGS; ÖGS; Panelists; Executive Board Members, Hoffmann J, Souchon R, Lebeau A, Öhlschlegel C, Gruber
G, Rageth C, Weber W, Harbeck N, Janni W, Kreipe H, Fitzal F, Resch A, Bago-Horvath Z, Peintinger F
German, Austrian and Swiss consensus conference on the diagnosis and local treatment of the axilla
in breast cancer.
Eur J Cancer 2013; 49: 2277-83
338
IF: 4,819
Gnant M
Role of Bisphosphonates in postmenopausal women with breast cancer
Cancer Treatm Rev 2014; 40: 476-84
339
IF: 6,024
Panhofer P, Ferenc V, Schütz M, Gleiss A, Dubsky P, Jakesz R, Gnant M, Fitzal F
Standardization of morbidity assessment in breast cancer surgery using the Clavien Dindo
Classification
Int J Surg 2014; 12: 334-9
IF: 1,436
340
Gnant M, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z, Mlineritsch B, Kwasny W, Singer C, Jakesz R, Dubsky
P, Fitzal F, Bartsch R, Steger G, Balic M, Ressler S, Cowens W, Storhoff J, Ferree S, Schaper C, Liu S, Fesl C, Nielsen T,
on
behalf of the
ABCSG
Predicting
distant
recurrence in receptor-positive breast cancer patients with limited
clinicopathological risk: using the PAM50 score in 1,478 postmenopausal patients of the ABCSG-08
trial
treated
with25:
adjuvant
Ann Oncol
2014;
339-45 endocrine therapy alone
IF: 7,384
341
Harmuth S, Wewalka M, Holst JJ, Nemecek R, Thalhammer S, Schmid R, Sahora K, Gnant M, Miholic J
Distal gastrectomy in pancreaticoduodenectomy is associated with accelerated gastric emptying,
enhanced postprandial release of GLP-1, and improved insulin sensitivity
J Gastrointest Surg 2014; 18: 52-9
IF: 2,361
2
Univ. Prof. Dr. Michael Gnant
342
Originalarbeiten
- 39 -
Gnant M, Bartsch R, Steger GG
HER2-positive breast cancer: a new piece of the puzzle
Lancet Oncol 2014; 15: 668-9
343
IF: 24,229
Rugo HS, Pritchard KI, Gnant M, Noguchi S, Piccart M, Hortobagyi G, Baselga J, Perez A, Geberth M, Csoszi T, Chouinard
E, Srimuninnimit V, Puttawibul P, Eakle J, Feng W, Bauly H, El-Hshimi M, Taran T, Sahmoud T, Burris HA
Incidence and time course of everolimus-related adverse events in postmenopausal women with
hormone-receptor-positive advanced breast cancer: insights from BOLERO-2
Ann Oncol 2014; 25: 808-15
IF: 7,384
344
Neven P, Markopoulos C, Tanner M, Marty M, Kreienberg R, Atkins L, Franquet A, Gnant M, Neciosup S, Tesarova P,
Barni S, Deschamp V
The impact of educational materials on compliance and persistence rates with adjuvant aromatase
inhibitor treatment: first year results from the Compliance of ARomatase Inhibitors AssessmenT In
Daily practice
Breast
2014; 23:through
393-9 Educational approach (CARIATIDE) Study
IF: 3,929
345
Filipits M, Nielsen T, Rudas M, Greil, R, Stöger H. Jakesz R, Bago-Horvath Z, Dietze O, Regitnig P, Gruber-Rossipal C,
Müller-Holzner E, Singer CF, Mlineritsch B, Dubsky P, Bauernhofer T, Hubalek M, Knauer M, Trapl H, Fesl C, Schaper C,
Ferree
S, Liu S,risk-of-recurrence
Cowens JW, Gnant M(ROR) score predicts risk for late distant recurrence after endocrine
The PAM50
therapy in postmenopausal women with endocrine-responsive early breast cancer: A study on 1,246
patients
from
the
ABCSG-8
trial
Clin Cancer
Res
2014;
20: 1298-305
IF: 7,837
346
Bartsch R, Frings S, Marty M, Awada A, Berghoff AS, Conte P, Dickin S, Enzmann H, Gnant M, Hasmann M, Hendriks HR,
Llombart A, Massacesi C, vonMinckwitz G, Penult-Llorca F, Scaltriti M, Wein W, Yarden Y, Zwierzina H, Zielinski CC, for
the
Biotherapy
Association
Present
and Development
Future Breast
Cancer(BDA)
Management - Bench to Bedside and Back: A Positioning Paper
of Academia, Regulatory Authorities and Pharmaceutical Industry
Ann Oncol 2014; 25: 773-80
347
IF: 7,384
Sahora K, Schindl M, Kuehrer I, Werba G, Fitzal F, Goetzinger P, Gnant M
Gemcitabine-based neoadjuvant chemotherapy for locally advanced pancreatic cancer does not
affect mortality and morbidity after pancreatic resection
European Surgery 2013; in press DOI 10.1007/s10353-013-0213-0
348
Bartsch R, Berghoff AS, Rudas M, Dubsky P, DeVries C, Sattlberger C, Mader MR, Sparber C, Fitzal F, Gnant M,
Rottenfusser A, Zielinski CC, Preusser M, Steger GG
Taxanes plus Trastuzumab compared to oral Vinorelbine plus Trastuzumab in HER2-overexpressing
metastatic breast cancer patients
Cancer Chemotherapy and Pharmacology 2014 [in press]
349
IF: 2,795
Foedermayr M, Sebesta M, Rudas M, Berghoff A, Promberger R, Preusser M, Dubsky P, Fitzal F, Gnant M, Steger G,
Welermann A, Zielinski C, Zach O, Bartsch R
BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological
complete response to taxan-based neoadjuvant chemotherapy
Cancer Chemother Pharmacol 2014; 73: 771-8
350
IF: 0,148
IF: 2,571
Steger GG, Greil R, Lang A, Rudas M, Fitzal F, Mlineritsch B, Hartmann BL, Bartsch R, Melbinger E, Hubalek M, Stoeger
H, Dubsky P, Ressler S, Petzer AL, Singer CF, Muss C, Jakesz R, Gampenrieder SP, Zielinski CC, Fesl C, Gnant M; on
behalf
of the and
Austrian
Breast and
Colorectal
Studycapecitabine
Group (ABCSGas neoadjuvant treatment for early breast
Epirubicin
docetaxel
with
or without
cancer: final results of a randomized phase III study (ABCSG-24).
Ann Oncol 2014; 25:366-71
IF: 7,384
2
Univ. Prof. Dr. Michael Gnant
351
Originalarbeiten
- 40 -
Tamandl D, Sahora K, Prucker J, Schmid R, Holst JJ, Miholic J, Goetzinger P, Gnant M
Impact of the reconstruction method on delayed gastric emptying after pylorus-preserving
pancreaticoduodenectomy: A prospective randomized study
World J Surg 2014; [published ahead of print Oct 12, 2013]
351
Exner R, Bago-Horvath Z, Bartsch R, Mittlboeck M, Retèl V, Fitzal F, Rudas M, Singer C, Pfeiler G, Gnant M, Jakesz R,
Dubsky P
The multigene signature MammaPrint® impacts on multidisciplinary team decisions in ER-positive,
HER2-negative early breast cancer
Brit J Cancer 2014; 111: 837-42
352
IF: 2,348
IF: 4,817
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year
breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised
trials.
Lancet 2014; 383: 2127-35
IF: 39,207
353
Gnant M
Modern therapeutic concepts of early breast cancer
Breast Care (Basel) 2014; 92: 85-6
354
IF: 0,911
Pfeiler G, Königsberg R, Fesl C, Greil R, Stoeger H, Singer C, Knauer M, Steger G, Seifert M, Dubsky P, Fitzal F, Balic M,
Bjelic-Radisic V, Mlineritsch B, Marth, C, Gnant M, on behalf of the ABCSG
Change of Body Mass Index (BMI) during adjuvant endocrine therapy and its impact on treatment
efficacy in premnopausal patients with breast cancer: an analysis of the ABCSG-12 trial
Brit J Cancer 2014 [in press]
356
IF: 4,817
Heitzer E, Mach M, Filipits M, Resel M, Graf R, Weiszenbacher B, Lax S, Gnant M, Wrba F, Greil R, Dietze O, Hofbauer F,
Boehm G, Hoefler G, Samonigg H, Schaberl-Moser R, Balic M, Dandachi N
Promoter methylation status of PCDH10, SPARC, and UCHL1 predict survival in stage II colorectal
cancer patients treated with or without 5-fluorouracil-based chemotherapy
Modern Pathology 2014; 27: 906-15
357
IF: 7,837
Sahora K, Schindl M, Kuehrer I, Eisenhut A, Werba G, Brostjan C, Teleky B, Ba'ssalamah A, Stift J, Schoppmann SF,
Gnant M
A phase II trial of two durations of bevacizumab added to neoadjuvant gemcitabine for borderline and
locally advanced pancreatic cancer
Anticancer Res 2014; 34: 2377-84
358
IF: 1,872
Gangl O, Sahora K, Kornprat P, Margreiter C, Primavesi F, Bareck E, Schindl M, Laengle F, Oefner D, Mischinger HJ,
Pratschke J, Gnant M, Fuegger R
Preparing for prospective clinical trials - a national initiative of an excellence registry for consecutive
pancreatic cancer resections
World J Surg 2014; 38: 456-62
359
IF: 3,373
Fitzal F, Filipits M, Rudas M, Greil R, Dietze O, Samonigg H, Lax S, Herz W, Dubsky P, Bartsch R, Kronenwett R, Gnant M
The genomic expression test Endopredict® is a prognostic tool for identifying risk of local recurrence
in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomized
within
the prospective
ABCSG 8 trial
Brit
J Cancer
2015 [in press]
IF: 4,817
2
Univ. Prof. Dr. Michael Gnant
360
Originalarbeiten
Foedermayr M, Sebesta M, Rudas M, Berghoff AS, Promberger R, Preusser M, Dubsky P, Gnant M, Steger GG,
Weltermann A, Zielinski CC, Zach O, Bartsch R
Association of TP53 mutations with TP53 codon 72 polymorphism and outcome in triple-negative
breast cancer patients.
J Hum Genetics 2015 [submitted]
361
IF:
Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, Noguchi S, Perez A, Rugo HS, Deleu I, Burris HA 3rd,
Provencher L, Neven P, Gnant M, Shtivelband M, Wu C, Fan J, Feng W, Taran T, Baselga J.
Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor
-2-negative advanced breast cancer: overall survival results from BOLERO-2.
Ann Oncol. 2014; 25: 2357-62
362
IF:
Berghoff A, Bartsch R, Preusser M, Ricken G, Steger GG, Bago-Horvath Z, Rudas M, Streubel B, Dubsky P, Gnant M,
Fitzal F, Zielinski CC, Birner P
Co-overexpression of HER2/HER3 is a predictor of imparied survival in breast cancer patients
Breast 2014; 23: 637-43
363
IF: 2,581
Blank PR, Filipits M, Dubsky P, Gutzwiller F, Lux MP, Brase JC, Weber KE, Rudas M, Greil R, Loibl S, Szucs TD,
Kronenwett R, Schwenkglenks M, Gnant M
Cost-Effectiveness of prognostic gene expression signature-based stratification of early breast
cancer patients
Pharmacoeconomics 2015: 33: 179-90
364
IF:
Zardavas D, Maetens M, Irrthum A, Goulioti T, Engelen K, Fumagalli D, Salgado R, Aftimos P, Saini KS, Sotiriou C,
Campbell P, Dinh P, von Minckwitz G, Gelber RD, Dowsett M, Di Leo A, Cameron D, Baselga J, Gnant M, Goldhirsch A,
Norton
L, Piccart M.
The AURORA
initiative for metastatic breast cancer.
Br J Cancer. 2014; 111: 1881-7
365
- 41 -
IF:
Sestak I, Cuzick J, Dowsett M, Lopez-Knowles E, Filipits M, Dubsky P, Cowens JW, Ferree S, Schaper C, Fesl C, Gnant M
Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of
Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen
or in Combination
Randomized Trials Using the PAM50 Risk of Recurrence IF:
Score
JAlone
Clin Oncol
2014; Oct 20 online
18,370
366
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)*
Patient-level meta-analysis of randomised trials of aromatase inhibitors versus tamoxifen in 31,920
postmenopausal women with ER-positive early breast cancer
Lancet 2015 [submitted]
367
IF:
Bergen E, .............. Gnant M,...., Bartsch R
Taxanes plus Trastuzumab compared to oral Vinorelbine plus Trastuzumab ind HER2-overexpressing
metastatic breast cancer
Breast Care 2015; [in press]
368
IF: 0,911
Coleman R, Powles T, Gnant M, bnm
Effects of adjuvant bisphosphonate treatment on early breast cancer disease outcomes: A meta-analysis of
individual patient data from randomised trials
Lancet 2015 [accepted]
IF: 20,000
2
Univ. Prof. Dr. Michael Gnant
369
Originalarbeiten
- 42 -
Sonnenblick A, Azim HA Jr, de Azambuja E, Francis P, Nordenskjöld B, Gutiérez J, Quinaux E, Mastropasqua MG, Ameye
L, Anderson M, Lluch A, Gnant M, Goldhirsch A, Di Leo A, Barnadas A, Cortes-Funes H, Piccart M, Crown J
Ten-year analyses of the BIG 2-98 phase III trial with an exploratory analysis on the role of Ki67 in
predicting benefit of adjuvant docetaxel in patients with estrogen receptor positive breast cancer
[submitted]
IF:
370
Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Knauer M, Moik M, Jakesz R, Seifert M, Taucher S, BjelicRadisic V, Balic M, Eidtmann H, Eiermann W, Steger G, Kwasny W, Dubsky P, Selim U, Fitzal F, Hochreiner G, Wette V,
Sevelda
P, Ploner
Bartsch R, with
Fesl C,
Greil R, on
behalf of the
ABCSGof tamoxifen versus anastrozole plus
Zoledronic
acidF,combined
adjuvant
endocrine
therapy
ovarian function suppression in premenopausal early breast cancer: of the Austrian Breast and
Colorectal
Cancer
Ann
Oncol 2015;
26; Study
313-20Group Trial 12
IF: 6,578
371
Gnant M, Sestak I, Filipits M, Dowsett M, Balic M, Lopez-Knowles E, Greil R, Dubsky P, Stoeger H, Rudas M, Jakesz R,
Ferree S, Cowens JW, Nielsen T, Schaper C, Fesl C, Cuzick J
Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive
hormone receptor positive early stage breast cancer treated with endocrine therapy: A combined
analysis
ABCSG-8
and ATAC using the PAM50 risk of recurrence score and Intrinsic
Subtype
Ann
Oncolof2015
[submitted]
IF: 6,578
372
Eisterer W, De Vries A, Öfner D, Rabl H, Koplmüller R, Greil R, Tschmelitsch J, Schmid R, Kapp K, Lukas P, Sedlmayer F,
Höfler G, Gnant M, Thaler J; ABCSG
Preoperative treatment with capecitabine, cetuximab and radiotherapy for primary locally advanced
rectal cancer--a phase II clinical trial.
Anticancer Res 2014; 34: 6767-73
373
IF: 1,872
Gnant M, Steger GG, Bartsch R
CDK4/6 inhibitors in luminal breast cancer
Lancet Oncol 2015; 16: 2-3
374
IF: 24,725
Bartsch R, Berghof AS, Vogl U, Rudas M, Bergen E, Dubsky P, Dieckmann K, Pinker K, Bago-Horvath Z, Galid A, Oehler
R, Zielinski CC, Gnant M, Steger GG, Preusser M
Activity of T-DM1 in HER2-positive breast cancer brain metastases
Neurooncology 2015 [submitted]
375
IF: 5,286
Markopoulos C, Neven P, Tanner M, Marty M, Kreienberg R, Atkins L, Franquet A, Gnant M, Neciosup S, Tesarova P,
Barni S, Deschamp V
Does patient education work in breast cancer? Final results from the global CARIATIDE study
Future Oncol. 2015; 11: 205-17
376
IF:
Hadji P*, Coleman RE*, Wilson C, Powles T, Clezardin P, Aapro M, Costa L, Body JJ, Markopoulos C, Santini D, Diel I, Di
Leo A, Cameron D, Dodwell D, Smith I, Gnant M, Gray R, Harbeck N, Thuerlimann B, Untch M, Cortes J, Martin M, Albert
US,
Conte PF,
Ejlertsen B, BerghinJ, early
M Kaufmann,
Holen. Consensus guidance for clinical practice from a
Adjuvant
bisphosphonates
breast Icancer:
European Panel.
Ann Oncol 2015 [submitted]
IF:
2